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Biopolymer-Nanotube Nerve Guidance Conduit Drug Delivery for Peripheral Nerve Regeneration 
Ohan Shant Manoukian, Ph.D. 
University of Connecticut, 2019 
Peripheral nerve injuries account for roughly 3% of all trauma patients with over 900,000 repair procedures 
annually in the U.S. Of all extremity peripheral nerve injuries, 51% require nerve repair with a transected 
gap. The current gold-standard autograft repair has several associated shortcomings, while engineered 
constructs typically offer suboptimal results only suitable for short gaps. In order to achieve enhanced 
peripheral nerve regeneration and greater functional recovery, we have developed a biodegradable, 
chitosan-based nerve guidance conduit (NGC) with aligned microchannel porosity and halloysite nanotubes 
for the sustained release of 4-Aminopyridine (4AP), a small molecule drug that promotes nerve conduction 
and neurotrophic factor release. In vitro studies characterized the polymer NGC system and confirmed the 
sustained release of 4AP. Human Schwann cells showed a dose-dependent elevation of critical proteins 
including nerve growth factor (NGF), myelin protein zero (P0), and brain derived neurotrophic factor 
(BDNF). When treated with 10 µg/mL 4AP, NGF, P0, and BDNF showed 128.58±0.57%, 310.75±11.92%, 
and 170.94±4.43% increases over no-drug control groups, respectively. When tested in vivo using a critical-
size (15 mm) rat sciatic nerve transection model, the results of functional walking track analysis, 
morphometric evaluations of myelin development, and histological assessments of various markers 
confirmed the equivalency of the drug-conduit repair to autograft controls. At 8 weeks post-operative, the 
sciatic functional index (SFI) of autograft (-44.89±4.73) was not statistically different from drug-conduit (-
45.12±4.45), while myelin thickness (G-ratio) evaluations also showed no statistical difference between 
autograft (0.61±0.10) and drug-conduit (0.65±0.06). The conduit’s aligned microchannel architecture and 
sustained release of 4-Aminopyridine may facilitate physical guidance of axons to distal target 
reinnervation, while increasing nerve conduction, and in turn neurotransmitter and neurotrophic factor 
release. Overall, our NGC facilitates more efficient and efficacious peripheral nerve regeneration via a drug 
delivery system that is feasible for clinical application, with potentially transformative implications. 
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CHAPTER 1: PERIPHERAL NERVE INJURY AND REGENERATION 
1.1. INTRODUCTION 
Peripheral nerve injury (PNI) occurs in roughly 2.8% of all trauma patients and can be extremely 
debilitating dependent on severity and classification of injury [1]. There are 50,000 procedures performed 
annually, in the United States alone, to repair damaged peripheral nerves, with an associated annual cost of 
7 billion USD [2]. Despite relatively low incidence, there is significant associated morbidity and peripheral 
nerve repair outcomes historically have been poor, particularly when treatment is delayed and/or damage 
is severe [3]. Axon regeneration can occur naturally, but is considered a generally slow process at a rate of 
1 mm/day, with any defect size greater than 3 cm often resulting in poor functional recovery [4-6].  
The severity and effects of PNI range from sensory and motor discomfort to severely debilitating 
impairment, dependent on the physiology of the injury. Treatment of severe PNI requires surgical 
intervention, most often the autograft, however nerve guidance conduits, functionalized for transportation 
and delivery of cells, growth factors, and drugs represent a new wave of neuroregenerative research with 
potentially transformative implications (Figure 1).  
Figure 1: Schematic illustration showing two approaches to bridging a peripheral nerve injury defect: the commonly-used 
autograft and a nerve guidance conduit, which may be used to deliver cells, growth factors, and/or various drugs. 
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This chapter aims to serve as a comprehensive, in-depth perspective on peripheral nerve injury, 
repair and regeneration, with a particular focus on nerve guidance conduits and drug delivery strategies. A 
comprehensive background of peripheral nerve injury and repair pathology, and an in-depth look into 
augmented nerve regeneration, nerve guidance conduits, and drug delivery strategies provides a state-of-
the-art perspective on the field. 
1.2. BIOLOGY OF PERIPHERAL NERVE INJURY AND REGENERATION 
1.2.1. Anatomy and Organization of Peripheral Nerves 
The peripheral nervous system (PNS) includes all parts of the total nervous system excluding the 
brain and spinal cord, which are classified as the central nervous system (CNS). It includes the peripheral 
nerves, the cranial nerves, spinal nerves, and neuromuscular junctions. Within the PNS, bundles of nerve 
fibers, or axons, conduct sensory and motor information to and from the CNS. Nerves are composed of 
nervous tissue, connective tissue supporting their structure, as well as blood vessels for nutrients. The most 
outer surface of a nerve is surrounded by a fibrous connective tissue known as the epineurium. One level 
in, axons are bundled into fascicles which are surrounded by the perineurium, composed of fibroblasts and 
collagen. Lastly, individual axons are sheathed by the endoneurium, composed primarily of oriented 
collagen fibers. 
All nerves connected to the spinal cord are classified as spinal nerves. In contrast, the nerves 
attached to the brain are classified as the cranial nerves, which are outside of the scope of this review. Spinal 
nerves are separated as sensory and motor and connect to the spinal cord as the dorsal nerve root and the 
ventral nerve root, respectively. Efferent (motor and autonomic) neurons receive signals from neurons in 
the CNS, while afferent (sensory) neurons receive signals from specialized cell types which are then sent 
to the CNS to provide sensory information or interneurons in the spinal cord for reflex responses [7].  The 
PNS is composed of two main cell types: neurons and neuroglia. Neurons are the primary functional 
elements of the PNS consisting of a cell body (soma), dendrites which are branching extensions that receive 
signals, an axon which is the primary extension which communicates signals through the neuron, and lastly 
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the axon terminal, which form junctions with other neurons or muscles and release neurotransmitters. The 
dendrites of the neuron receive excitatory or inhibitory signals from other cells and transmit electrical 
signals to the neuron’s soma, which are then conducted as electrical impulses (action potentials) down the 
axon. 
In the PNS, axons are classified as myelinated or unmyelinated based on the presence of an 
insulating myelin sheath surrounding the axon. Made up of proteins and fatty acids, myelin sheath is 
produced by Schwann cells around the axon and acts as an electrical insulator. Thus, the myelin serves to 
increase the axon potential conduction velocities, which is particularly important for extended axons, where 
unmyelinated axon conduction velocities range from 0.5-10 m/s and myelinated axons conduct up to 150 
m/s (Table I) [8].  
1.2.2. Peripheral Nerve Injury 
In 1942, sir Herbert Seddon became the first to classify nerve injuries according to the severity of 
demyelination, damage to axons, and damage to surrounding tissues (Table II) [8]. Neurapraxia is the 
mildest form of injury, characterized by focal demyelination with no damage to axons or surrounding 
tissues, typically occurring from mild compression of the nerve. Demyelination typically causes decreases 
in conduction velocity, however depending on severity, it can cause conduction blocks and muscle 
Table I: Various classes of nerve fibers and their associated properties, location, and functions. 
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weakness. The next level of injury, axonotmesis, involves focal demyelination and damage to the axons, 
while maintaining continuity of the surrounding nerve tissues. Lastly, neurotmesis refers to the most severe 
form of nerve injury where there is a full transection (segmental defect) of the axons as well as all the 
surrounding connective tissue layers [8]. With such an injury, there is complete discontinuity of the nerve 
and surgical repair is required for recovery. 
To differentiate the extent of damage to surrounding connective tissues, namely the epineurium, 
perineurium, and endoneurium, sir Sydney Sunderland expanded on Seddon’s scheme with a five-grade 
PNI classification (Table II) [9]. The first and second grades of the Sunderland classification correspond 
to neurapraxia and axonotmesis, respectively, as described above. Grade III, IV, and V injuries are 
described as damage to the axon along with the associated endoneurium, perineurium, and epineurium, 
respectively. With damage to the connective tissue layers surrounding the axons, there is increased 
likelihood of variable recovery, often incomplete, due to misdirection of regenerating axons which may be 
unable to innervate sensory or muscle targets. Grade IV injuries lead to localized neuroma formation 
resulting from internal hemorrhage and fibrous tissues blocking the distal growth of regenerative axons, 
whereas grade V injuries, with complete nerve discontinuity, result in end-bulb neuroma.  
Table II: Classifications of nerve injuries according to Sunderland and Seddon with associated descriptions and recovery. 
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1.2.3. Compression Injuries 
Compression injuries, different from crush injuries, fall under the Seddon class of neurapraxia, or 
Sunderland’s grade I for PNI. These injuries are generally characterized by focal demyelination, localized 
to the site of compression, with no damage to the axon or surrounding connective tissues. Carpal tunnel 
syndrome, tarsal tunnel syndrome, as well as sciatica are all examples of compression injuries of nerves 
[10]. Here, normal nerve morphology is still present with adequate neuromuscular junctions. However, 
focal demyelination is characteristic of a compression injury and is shown by an increased G-ratio, a ratio 
of the axon diameter to the nerve fiber (axon plus myelin sheath) diameter. Similarly, there is a marked 
decrease in the distance between adjacent nodes of Ranvier, known as the internodal length.   
1.2.4. Crush and Transection Injuries 
Crush injuries are typically the result of acute blunt-force trauma, causing traumatic compression 
of the nerve. This can include trauma from any blunt object, for example a bat, that does not transect the 
nerve [8]. The resultant crush injury can be categorized, in part or wholly, by any of the classes in both the 
Seddon and Sunderland schemes. Thus, the severity of crush injuries is highly variable and dependent on 
the magnitude of trauma and location of injury. In contrast, transection injuries, representing grade V nerve 
injuries, show a complete discontinuation of the nerve where axons are transected and there is a physical 
gap, or segmentation, between the proximal and distal ends. Transection injuries are commonly due to 
lacerations from a sharp object such as a knife, blade, or glass shard, as well as gunshot wounds and 
explosions [11]. It is important to note that for ballistic wounds, namely gunshot and explosive 
fragmentations, often times there may be a combination of both crush and transection of the nerve, partially 
associated with shear and compressive stresses caused by the shockwave of the passing of the projectile or 
fragment through tissues. 
1.2.5. Wallerian Degeneration 
Upon PNI, Wallerian degeneration is initiated distal to the injury zone, starting with axonal 
breakdown, as a measure to alleviate abnormal axon regeneration (Figure 2). This intrinsic breakdown of 
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distal axons and myelin is the initiator of the degeneration and repair cascade, which does not alone include 
the nerve, but is a multi-cellular complex response involving multiple components [12-14]. The 
coordination and recruitment of macrophages, neutrophils, and adaptive cells (T and B cells) along with 
de-differentiating Schwann cells is vital to the successful repair and regeneration of the injured nerve [15]. 
These cells are recruited to the site of injury within the initial hours and days after nerve injury, with the 
primary goals of clearing inhibitory debris and the production of an environment supportive of nerve 
regeneration. Despite aggressive recruitment and initiation of axonal degeneration, detached axons remain 
intact for several days after the initial injury and have been shown to be capable of transmitting action 
potentials when stimulated.  
Figure 2: The various stages of peripheral nerve injury, repair, and regeneration. 
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The involvement of macrophages in axonal degeneration was long thought to be limited to removal 
of myelin debris. However, macrophages along with Schwann cells help promote an environment 
supportive of axonal regeneration with the release extracellular matrix (ECM) proteins, neurotrophins, 
cytokines, and chemokines. Mainly originating from circulating hematogenous monocytes, the recruitment 
of macrophages begins 2-3 days post-injury and peaks at 7-days post-injury [16-19]. Trophic cues released 
by de-differentiating Schwann cells as a response to peripheral nerve injury initiate and regulate 
macrophage infiltration. Schwann cell released factors include Monocyte Chemoattractant Protein-1 (MCP-
1/CCL2), IL-1α, IL-1β, S100A8, S100A9 as well as ECM proteins including prominently collagen VI [20-
23]. Moreover, localized macrophages also release similar factors including MCP-1, IL-1α, and IL-1β 
which further recruit macrophages to the site of injury in a positive-feedback loop mechanism [22-25]. 
1.2.6. Endogenous Nerve Repair and Regeneration 
Initially, swelling occurs at both the proximal and distal ends of the damaged nerve, resulting from 
futile continuation of retrograde and anterograde axonal transport [26]. This eventually leads into the 
breakdown of the distal stump, via the granular disintegration of the cytoskeleton [27]. This breakdown is 
preceded shortly by the influx of extracellular ions, namely, Ca+ and Na+, which serve to recruit nearby 
macrophages to the site via signals from Schwann cells. Furthermore, mRNA of brain-derived neurotrophic 
factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) have shown marked upregulation in 
the distal stump.  
In contrast to the distal stump breakdown, changes in the proximal stump vary highly based on the 
location of the injury with relation to the neuronal body. If the injury is in close proximity to the neuronal 
body, apoptosis may occur [28]. Otherwise, the breakdown of the proximal stump is typically limited, only 
progressing to the first node of Ranvier. The primary focus of the proximal portion of the nerve is 
chromatolysis – the changing of its cell genetic makeup, to focus on a regeneration phenotype [8]. There is 
an endogenous upregulation of neuroprotectant proteins, for example heat-shock protein-27, in an effort to 
promote neuronal survival [29, 30]. Nerves that undergo this process have shown upregulation of protein 
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associated with growth including gap-43, tubulin, and actin, while neurofilament proteins, involved with 
axonal maintenance, are downregulated [31-33]. 
Dependent on the type and severity of nerve injury repair and recovery can occur in two primary 
ways: through collateral branching of intact axons or by the regeneration of injured axons [34]. In slight to 
moderate injuries, collateral branching begins in the first week and continues for anywhere from 3-6 
months, until recovery and reinnervation. It is interesting to note that there are initially more sprouting 
axonal branches than actual number of nerves innervating a target-organ [35]. The branches that do not 
receive neurotrophic factors from the target-organ eventually undergo a process to degenerate [36, 37]. In 
contrast, in more severe injuries, where a vast majority of nerve axons have been affected, the primary 
mode of recovery is axonal regeneration [38]. The regeneration occurs in three broad phases: Wallerian 
degeneration, axonal regeneration, and target-organ reinnervation.  
1.2.7. Schwann Cell Involvement 
Typically known for their myelin-producing abilities, Schwann cells are vital, primary mediators 
in triggering the cascading events in Wallerian degeneration and changes in their protein expression are 
critical to axon regeneration [8]. The ability for Schwann cells to de-differentiate and later re-differentiate 
enables them to control their cellular behavior dependent on the situation. In an immediate response to PNI, 
Schwann cells detached from axons in the distal nerve begin to de-differentiate and alter gene expression 
[39-41]. Changes in protein and factor expression take place as soon as within 48 hours where Schwann 
cells cease myelin production, in turn upregulating regeneration-associated genetic markers for example, 
GAP-43 and neurotrophic factors such as Nerve Growth Factor (NGF), BDNF, GDNF, etc. [42-44]. In 
conjunction with this increase in regenerative factor expression, Schwann cells begin to proliferate, 
reaching peak proliferation around 4 days post-injury. These proliferating cells align in their basal lamina 
tubes to form the notorious Bands of Büngner, providing a supportive basis for regenerating axons [45, 46].  
In addition to promoting regeneration, Schwann cells play a key role in the removal of myelin 
debris, which may otherwise hinder repair, acting as a physical barrier to regenerating axons. Post-PNI, the 
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myelin sheath of Schwann cells remains to form small ovoids [46], which contain molecules that are 
inhibitory to axonal growth such as myelin-associated glycoprotein (MAG) and oligodendrocyte-myelin 
glycoprotein (OMgp) [47, 48]. Schwann cells possess the ability to degrade their own myelin and 
phagocytose extracellular debris, making them one of the major phagocytic cells for the first 5 days after 
PNI [49]. This Schwann-cell mediated myelin degradation is highly regulated by the phospholipase-A2 
(PLA2) enzyme family, where cytosolic and secreted PLA2 hydrolyze the phospholipid phosphatidylcholine 
into lysophosphatidylcholine, eliciting myelin breakdown, and arachadonic acid [12, 50]. PLA2 levels 
remain upregulated in Schwann cells, as well as macrophages, for 2 weeks, correlating to the time course 
of Wallerian degeneration after PNI, where the return of PLA2 to basal levels occurs approximately 3 weeks 
post-PNI, associated closely with axon regeneration and remyelination [51]. 
Despite the efficient and effective response of Schwann cells to control and combat the effects of 
PNI, their efforts that successfully promote axon regeneration are time-dependent. Schwann cells in the 
distal nerve typically struggle to survive and facilitate axon regrowth, with their ability to survive declining 
within 8 weeks of injury and denervation [41, 52]. Denervated Schwann cells die by apoptosis within 
months after PNI, with persistent cells yielding to atrophy, and this time-sensitive loss of support is 
generally considered one key factor that limits the successful regeneration of peripheral nerve axons over 
long distances [44, 53-56]. 
1.3. AUGMENTED PERIPHERAL NERVE REGENERATION 
1.3.1. Tissue Grafts for Nerve Repair 
1.3.1.1. Autograft 
Highly regarded as the gold-standard for the treatment of nerve lesions, the autograft consists of 
harvesting a healthy segment of nerve directly from the injured patient [57]. The autograft offers a great 
advantage in that the tissue has minimal chance of tissue rejection (nonimmunogenic), having been 
harvested from the same patient. Furthermore, autografts provide appropriate neurotrophic factors and 
viable Schwann cells for axonal regeneration and nerve repair. The size of the nerve gap and the location 
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of the injury often play a large role in deciding the choice of autograft [58], with the Sural nerve serving as 
the most commonly used autograft [59, 60]. The first clinical experiments with autograft for nerve repair 
date back to 1870 in which Philipeaux and Vulpian reported performing the first nerve autografts in dogs 
[61]. Despite its successes, the autograft offers a number of considerable disadvantages, namely the 
necessity of an additional surgical procedure, causing another nerve injury. This results in the loss of 
function at the donor site, often termed donor site morbidity, and may lead to the formation of a painful 
neuroma [14, 62].  
1.3.1.2. Allograft 
Nerve allografting, or the use of donor-related or cadaveric nerve allografts, is an alternative to the 
traditional autograft technique for segmental nerve injuries. The allotransplantation of tissues, including 
nerve allografts, require systemic immunosuppression in order to limit the risks of potential host system 
rejection. The health hazards and vulnerability associated with systemic immunosuppression and morbidity 
of immunomodulatory therapy severely limits the widespread use of nerve allografts. Unlike organ 
transplantation, nerve allografts do not require lifelong immunosuppression. Rather, systemic 
immunosuppression can be terminated within approximately 24 months, once adequate host Schwann cells 
have migrated into the nerve allograft [58]. Recent advances in medicine and immunology research have 
led to several techniques to limit antigenicity and the risk of rejection of allografts including irradiation, 
cold preservation and freezing, and lyophilization [63-67]. The use of allografts relies upon the viability of 
both host and donor Schwann cells, with the native and transplanted Schwann cells responsible for proper 
remyelination and acting as the source for neurotrophic factors [68]. There remains a high research interest 
in biomedical and biological fields to understand the host response to nerve allograft transplantation, in 
order to elucidate mechanisms and techniques to mitigate such responses.  
1.3.2. Tissue Engineering Strategies: Biomaterials and Nerve Guidance Conduits 
Nerve guidance conduits (NGC) represent a multidisciplinary, multidimensional, and cutting-edge 
transformative material platform to apply tissue engineering principles and properties (biodegradability, 
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biocompatibility, mechanical mimicry, etc.) to develop biomaterial-based scaffolding to aid in nerve repair 
and regeneration (Figure 3).  
Often polymer-based, NGCs are designed to bridge nerve defects in order to guide the regenerating 
axons to the appropriate distal target – significantly improving the efficacy of repair and target 
reinnervation. The development of NGCs requires input and expertise in biomaterials, biomedical 
engineering, regenerative medicine, pharmaceuticals, neurobiology, and orthopedic surgery. Over the last 
decade, vast research efforts have been devoted to NGCs of various compositions, with varying novelties, 
functionalizations, and capabilities, including the ability to carry and deliver pharmaceutical payloads, 
small-molecule drugs, and growth factors (Figure 4).  
Figure 3: Tissue engineering scaffolds and biomaterials are versatile tools for the repair and regeneration of various tissues. 
Figure 4: Nerve guidance conduits are engineered tubes which are used to bridge peripheral nerve gaps, capable of promoting 
key attributes to facilitate quicker and more efficacious peripheral nerve repair and regeneration. 
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1.3.2.1. Natural Materials for Nerve Regeneration 
There are several key advantages which make natural polymers particularly appealing for 
biomedical, tissue engineering, and regenerative medicine applications. Most notably, natural polymers are 
well-known for their biodegradability, biocompatibility, and economic availability (natural abundance with 
lower associated costs). Despite their advantages, which make natural materials particularly well-suited for 
nerve regeneration applications, natural materials tend to have weak mechanical properties which often 
serves as a profound obstacle for feasible regenerative strategies. Overcoming such limitations requires the 
modification of materials in order to enhance physiochemical properties including mechanical strength, 
degradation/swelling, and stability. Perhaps the most widely used modification is crosslinking, which refers 
to the chemical process by which one polymer chain is linked to another. Crosslinking often results in 
higher tensile strength, greater modulus, improved fluid resistance, better crush resistance, etc. Another 
common method to create more useful materials is the science of composites – blending natural polymers 
with other materials to achieve suitable properties.  
Among the countless number of natural materials used for fabrication of NGCs, or otherwise for 
repair of PNI, chitosan [69], collagen [70], and silk fibroin [71] have garnered significant attention due to 
their biodegradability, biocompatibility, and nontoxic properties. Various studies have shown optimistic 
results with regards to nerve repair, showing myelinated axons, recovering nerve functionality, and 
colonization of nervous tissue. Other materials of interest for nerve regeneration applications include gelatin 
[72], hyaluronic acid [73], and fibrin [74].  
1.3.2.2. Synthetic Materials for Nerve Regeneration 
Many synthetic materials are popularly used for various tissue engineering and regenerative 
medicine applications, including polycaprolactone (PCL) [75], polylactic acid (PLA) [76], polyglycolic 
acid (PGA), polylactic-co-glycolic acid (PLGA) [77, 78]. Such materials possess adequate mechanical 
strength and structural integrity, however they possess variable levels of biodegradation. Non-degradable 
synthetic polymers have also been used for such applications, silicone being the prime example, however 
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these induce complications of foreign body response, inflammation, and secondary surgery. PCL [79], PLA 
[80], PGA [81], and PLGA [82] have all been developed and tested as NGCs for nerve regeneration showing 
successful in vitro and in vivo results, achieving improved nerve diameter, myelination, and functional 
recovery. 
1.4. EXOGENOUS NEUROTROPHIC GROWTH FACTORS 
1.4.1. Biofunctionalization by Neurotrophic Factors 
Neurotrophic factors are known to provide significant regulation for Schwann cell (SC) 
myelination in peripheral nerve development through various mechanisms. For each growth factor, there 
are different signal transduction pathways used and concentration levels necessary to encourage axonal 
regrowth and remyelination. The neurotrophic factors that act to enhance recovery include nerve growth 
factor (NGF), glial cell-line derived neurotrophic factor (GDNF), brain-derived neurotrophic factor 
(BDNF), neutrohphin-3 (NT-3), and neutrohpin-4/5 (NT-4/5), which will all be examined later on in this 
section. The specificity for neurotrophic factor levels needed in injury repair can be seen in Richner et al.’s 
identification that NGF is required for the survival of nociceptive and thermoceptive dorsal root ganglion 
(DRG) neurons, NT-3 is necessary for proprioceptive neurons, and BDNF and NT-4/5 are required for 
motor neurons survival [83]. The effects of the neurotrophic factors are harnessed through direct protein 
delivery, stimulating their expression or using cell therapies to deliver the proteins locally. 
In this section, the mechanisms that allow these factors to encourage regeneration will be explored 
using experimental evidence along with the presentation of challenges that must be overcome to harness 
their regenerative potential. The effects of these factors will be shown through research studies involving 
their direct and indirect use. Later on, the biomedical engineering strategies designed to overcome these 
challenges for delivery will be presented and analyzed. 
1.4.2. Challenges in Neurotrophic Growth Factor Delivery 
Neurotrophic growth factors pose difficulty in drug delivery systems based on pharmacokinetics, 
pharmacodynamics and physiochemical properties, requiring significant regulation for their release. In 
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order to maintain their stability, growth factors must be processed in mild conditions, including ambient or 
low temperatures, in the absence of organic solvents, with stabilizing additives, and in aseptic sterilization 
[84]. To overcome the time-dependent limitation, studies often test stimuli that encourage the expression 
levels of several neurotrophic factors. Guo et al.’s 2018 study using chitosan conduits containing 
simvastatin/Pluronic F-127 hydrogel was found to promote peripheral nerve regeneration by upregulating 
the expression of pleiotrophin, hepatocyte growth factor, VEGF and GDNF [85]. Another mechanism that 
is commonly used to stimulate growth factor expression is stimulating neuronal activity through the use of 
electrical stimulus or exercise for the upregulation of BDNF and other neurotrophic factors [86]. These 
types of treatments have shown to be especially effective in pre-clinical testing. Gordon et al. demonstrated 
the efficacy of electrical stimulation correlated to an acceleration of axon outgrowth and increased 
motoneuron regeneration. 
1.4.3. Neurotrophic Growth Factors for Peripheral Nerve Regeneration 
1.4.3.1. Nerve Growth Factor 
Nerve growth factor (NGF) has been known to play a vital role in developing sympathetic and 
sensory nerve cells, directing growth of their regenerating axons [87]. NGF is upregulated following PNI 
and functions through binding to Trk receptors, activating a regulatory pathway that induces cytoskeleton 
assembly and the outgrowth of neurites (Figure 5). Neurotrophins that bind to Trk receptors activate Ras-
extracellular signal-regulated kinase (ERK) pathway leading to enhanced neurite outgrowth and axon 
survival. NGF has been used in a range of PNI treatment studies, including Kuihua et al.’s 2013 study 
testing NGF encapsulated in aligned SF/P(LLA-CL) nanofibers to sustain release of NGF over 60 days. 
Results suggest that this sustained release mechanism using nanofibers effectively enhanced regeneration 
[88]. Since NGF degrades quickly, these encapsulation methods help extend the life span for the NGF 
supply significantly by preventing degradation.  
While this pathway can be stimulated by using an exogenous supply of NGF, the pathway can also 
be stimulated at several points by common pharmacologic agents (e.g. erythropoietin, tacrolimus, 
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geldanamycin, acetyl-l-carnitine, and n-acetyl-cysteine), which have all been explored as potential 
treatments[89]. An example using one of these stimuli in combination with neurotrophic factors can be seen 
in Labroo et al.’s study treating chicken embryos in vitro with the immunosuppressant, FK506 (tacrolimus), 
along with GDNF and/or NGF. This combination therapy significantly increased neuroregenerative activity 
potentially due to FK506 enhancing the growth factors’ efficacy at the injury site [90].  
1.4.3.2. Brain-Derived Neurotrophic Factor 
Brain-derived neurotrophic factor (BDNF) interacts with p75 and TrkB receptors leading to 
enhanced myelination in Schwann cells, promotion of neuronal cell survival, and enhancement of neurite 
outgrowth. In 2016, its mechanism was investigated by Lin et al., finding that this activity is due to BDNF 
activating the JAK/STAT pathway in Schwann cells, leading to cytokine production that encourages 
regeneration [91]. A significant amount of research has been focused on investigating pathway 
intermediates to control stimulatory effects. The molecule netrin-1 is an important molecule for nerve 
regeneration and its overexpression was found to increase the expression of BDNF and NGF, leading to 
improved functional recovery and the increased presence of Schwann cells when using transplanted bone 
marrow mesenchymal stem cells that produce the molecule [92]. This molecule is a potential target for 
stimulating BNDF’s signaling pathway. 
Figure 5: A simplified schematic illustrating the biochemical pathways for NGF- and BDNF-mediated neuronal repair and 
regeneration. Both NGF and BDNF are upregulated following PNI and function through binding to Trk receptors, activating 
a regulatory pathway that induces cytoskeleton assembly, axonal outgrowth, and myelination. 
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The levels of BDNF concentration have a direct influence on axonal regeneration, with low 
exogenous BDNF doses found to enhance motor neuron axon regeneration while high doses inhibit 
regeneration both initially and long-term following transection, exhibiting dose-dependent facilitation and 
inhibition [83, 93]. A 2012 study identified that BDNF expressed in the neurons and Schwann cells work 
together to facilitate motor axonal regeneration, potentially mediated by retrograde signaling on the TrkB 
receptors of growing axons from the Schwann cell BDNF [94]. These findings led to Gordon et al.’s 
investigation of exercise and electrical stimulation as a therapeutic treatment for PNIs, due to the 
upregulation of BDNF and other neurotrophic factors [86]. Arbat-Plana et al.’s 2017 study found that a 
regulated physical exercise regimen offers a better TrkB activation method than using pharmacological 
TrkB pathway agonists, attributed to the increase in BDNF [95]. This treatment is a candidate with strong 
clinical potential without the limitations associated with drug delivery. 
1.4.3.3. Neurotrophin-3 
Neurotrohin-3 (NT-3) has been found to have reduced concentration levels for up to two weeks 
following nerve transection with the indication that Schwann cells are the factor’s primary source. In early 
studies, the exogenous application of NT-3 led to maintained conduction velocity supporting NT-3 as a 
molecule that promotes nerve regeneration. Because persistent denervation causes Schwann cell atrophy 
and the reduction of neurotrophic factor production, an exogenous NT-3 supply offers a viable option for 
stimulating functional recover because Schwann cells require NT-3 during the early myelin developed in 
regeneration [83]. Wang et al.’s 2016 study identified that NT-3 bound to collagen binding domain 
promoted ordered axon outgrowth and enhanced functional recovery [96]. NT-3 operates through the 
activation of TrkC and evidence suggests that it also drives regeneration through GABA excitation 
potentiating presynapses [97]. Based on the information presented, neurotrohpin-3 and agonists for its 
pathway are often tested for regenerative potential. 
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1.4.3.4. Glial Cell-Derived Neurotrophic Factor 
In a 2018 study by Nagai et al., it was determined that decreased glial cell-derived neurotrophic 
factor (GDNF) leads to decreased levels of m2 muscarinic acetylcholine receptor (m2MAchR) and gamma-
aminobutyric acid receptor α1 (GABAARα1) in injured motoneurons. Following injury, GDNF levels 
decrease from normal levels and reach their lowest point around 3-5 days later, returning to standard levels 
after 2 weeks [98]. A 2016 study by Tajdaran et al. used the a drug delivery system with PLGA 
microspheres to deliver exogenous GDNF, finding increased counts for motor and sensory nerves when 
repaired immediately after inflicting injury and in a delayed repair [99]. Marquardt et al. used GDNF 
preconditioning to overcome the negative effects that result from mismatching Schwann cells and neuron 
combinations (“i.e. motor neurons/muscle nerve-derived SCs vs. motor neurons/cutaneous nerve-derived 
SCs”) demonstrating the clinical potential for this treatment [100]. Exogenous supplies of GDNF 
compensate for the decreased level endogenous production to promote redevelopment. 
1.4.3.5. Neurotrophin-4/5 
Neurotrophin-4/5 (NT-4/5) is able to enhance peripheral nerve regeneration through the signal’s 
interaction with two different neurotrophin receptors, TrkB and p75NTR, like the BDNF signaling pathway 
[101]. Similar to NT-3, there is a downregulation of NT-4/5 mRNA levels following peripheral nerve injury 
with the levels returning around 2 weeks post injury. In rodent nerve injury models, NT-4/5 was found to 
restore motor axon growth while improving the axon count, diameter and the myelin thickness [83]. English 
et al. identified that axon regeneration enhancement was dependent on the expression of NT-4/5 in the 
proximal nerve stump when using treadmill training as a stimulant, while changes in the distal segment did 
not have the same neuroregenerative effects. Electrical stimulation and treadmill training were found to be 
effective in enhancing axon regeneration, which led English et al. to agree with previous researchers in that 
the stimulants likely cause the autocrine or paracrine neurotrophic signals [102]. While there have been 
minimal studies testing the direct application of NT-4/5 to the injury site, these results support the 
molecule’s potential for enhancing regeneration. 
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1.4.3.6. Vascular Endothelial Growth Factor 
Vascular endothelial growth factor (VEGF) was initially discovered as an angiogenic factor based 
on the cellular signaling mechanisms for VEGF-A. Despite this, VEGF-B has downstream signaling targets 
that regulate both the nervous and cardiovascular systems with activity distinctly different from VEGF-A. 
In the peripheral nervous system, VEGF-B has protective effects that mediate repair after injury that are 
independent of its vascular effects. Evidence suggests that VEGF-B signals through PI3K in order to 
elongate neurites along with an upregulation of pigment epithelium-derived factor (PEDF) with 
dopaminergic pathways requiring further investigation [103]. In testing resveratrol’s effects on PNI 
regeneration, resveratrol was found to stimulate p300 acetyltransferase-mediated VEGF signaling of the 
ventral spinal cord for rats that experienced sciatic nerve injury and lead to improved motor function and 
repair [104]. Based on these results, resveratrol has regenerative potential and should be studied 
mechanistically. In a 2017 study by Di et al., an exogenous supply of VEGF-B was found to promote 
recovery and trophic function through reactivating PI-3K/Akt-GSK-3β-mTOR signaling, attenuating 
neuronal oxidative stress, and elevating PEDF expression [105]. These finding support the use of VEGF-B 
as a potential therapeutic agent and, with the evidence from previous studies, can have its pathway 
stimulated by drug molecules. 
1.5. DRUG DELIVERY STRATEGIES AND CELL THERAPIES 
1.5.1. Drug Delivery via NGCs 
Various mechanisms can be used to incorporate small drug molecules and growth factors of interest 
into the NGC matrix. In a 2013 study, Tang et al. used an NGF concentration gradient in conduits, created 
using adsorption of the growth factor in a solution to form a gradient with the molecules immobilized in 
the PLCA membranes. This method had results comparable to the autograft standard and superior to the 
membrane with a uniform nerve growth factor concentration [106]. Recently, immunotherapy approaches 
have also been explored for nerve regeneration. Mokarram et al. showed early modulation of the immune 
environment at the site of nerve injury by delivering fractalkine, a chemokine protein found commonly in 
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neural cells, using a nerve guidance conduit [107]. The authors of the paper showed dramatic increases in 
regeneration using both histological and electrophysiological assessments to characterize the efficacy of 
their delivery system, potentially introducing an alternative paradigm to facilitate the endogenous repair 
undergone by nerve tissues after PNI. In a 2010 study, Wood et al. created an affinity-based delivery system 
using various neurotrophic factors and polymerizing silicone tubes with a fibrinogen solution for sustained 
delivery. In this study, the test group using the delivery system for GDNF produced superior or equivalent 
functional recovery and motor nerve regeneration results, when compared to an isograft model [108]. This 
affinity based method is commonly used involving heparin and heparin sulfate to protect growth factors 
from proteolytic cleaving while also making them available to trigger signal transduction pathways [109]. 
The structure of the scaffold itself can also be altered to promote sustained delivery of a given drug 
molecule. Hong et al. used multilayered PLGA scaffold (the first layer aligned for topographical cues and 
the following two layers randomly oriented) to create different rates for biodegradation and controlled 
release of growth factors, where the scaffold can be tailored chemically and morphologically to provide 
specific cues to the regenerating tissues. The in vivo study found positive results through behavioral tests, 
mechanical allodynia analysis and morphological studies of the tissue [110]. Madduri et al. argues that the 
further investigation in a clinical trial is challenged by the rapid release of these factors from the NGC 
matrix and the harsh and difficult conditions necessary to process these devices [109]. 
Small-molecule drugs and growth factors can also be suspended in matrices that fill the lumen of 
NGCs (intraluminal matrix) in order to provide local release. The active material used in these matrices can 
be laminin, heparin, heparin sulfate, alginate, and hydrogel-forming collagen. The matrices are viscous in 
order to provide slow fluid exchange coupled with rapid release of growth factors. Molecular interactions 
with the growth factors can vary, including ionic, electrostatic, and hydrophobic interactions along with 
ligand-receptor binding based on the physiochemical nature of the growth factors [84]. An example of a 
luminal filler that mimics the extracellular matrix is the dual-component hydrogel system (cGEL) that 
Kohn-Polster et al. designed and found to be superior to the use of empty conduits by providing mechano-
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biochemical stimulation for regeneration [111]. Gnavi et al. used biocompatible and biodegradable gelatin-
based hydrogel to deliver VEGF and was found to prevent the growth factor’s degradation for it to promote 
nerve regeneration [112]. The matrix used in the lumen must be specialized for the delivery system to 
optimize regenerative effects. 
1.5.2. Microspheres for Drug Delivery 
NGC are commonly combined with polymeric microspheres as a method to deliver growth factors 
and maintain dose regimens. Growth factors get loaded into the microspheres and then incorporated into 
the NGC walls or the lumen to degrade over time, releasing the drug to enhance regeneration. Tajdaran et 
al. reports that PGLA is the most widely used polymer for microsphere drug delivery, typically ranging in 
size from 200nm to 600µm with the release time ranging from one week to several months, based on the 
composition of the microspheres. They also can be used to hold drugs with a variety of properties and drug 
profiles to promote sustain release to an injury site [113]. 
In a 2017 study on the effects of timed EPO release using PLGA microspheres, Zhang et al. showed 
that rats with this treatment mechanism had better recovery that those undergoing intraperitoneal injections 
along with the positive and negative controls, seen through functional, electrophysiological and histological 
analysis [114]. While intraperitoneal injections are often used in these drug delivery studies, this study 
suggests that release using microsphere promote improved regeneration results without requiring repeat 
injections. Using PLGA microspheres for PNI treatment Tajdaran et al.’s 2015 study tested the sustained 
released of tacrolimus (FK506) as a method to reduce drugs systemic effects of immunosuppression. FK506 
was added to a fibrin gel that was then encapsulated into PLGA microspheres that released FK506 over 28 
days, finding enhanced neurite outgrowth and nerve regeneration without systemic immunosuppression 
[115]. Using similar methods they also tested GDNF in fibrin gel incorporated into PLGA microspheres 
which improved axon regeneration along with fiber maturity [99]. This study demonstrates that 
microspheres are useful for harnessing local effects of drug molecules and limiting systemic effects.  
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While PLGA is the most commonly used material for microspheres because of its FDA approval, 
other materials, like gelatin, can also be used as the base molecule for microspheres. To encourage the 
sustained release of neurotropic factors, Matsumine et al. performed a study using basic fibroblast growth 
factor (bFGF) in acidic gelatin hydrogel microsphere compared to silicone tubes infused with bFGF. The 
bFGF microspheres resulted in faster regeneration and more mature nerve axons after 7 weeks, supporting 
the positive influence of sustained, controlled release of stimulatory molecules [116]. To further study the 
effects of this delivery method, nerve recovery should be tested varying the size of the microspheres to 
optimize regenerative effects based on the surface area to volume ratio. Microsphere solutions can also be 
used to fill the luminal space of NGCs to provide similar effects as when they are incorporated into the 
conduit structures. Chen et al. used this method by injecting microspheres with NGF into the lumen of 
conduits using a microsyringe, finding no outflow from this region into the surrounding tissues. While 
testing the effect of icariin (an element of Epimedium extract) on PNI recovery, they found that both 
suspended icariin and microspheres with NGF in the lumen promoted improved nerve conduction velocity 
and fiber myelination [117]. 
1.5.3. Cell Therapies for Peripheral Nerve Regeneration 
1.5.3.1. Schwann Cells 
Schwann cells play a crucial role for creating an environment conducive to recovery after peripheral 
nerve injury. Barton et al. explains how, when damaged axons transition from the “conducting” phenotype 
to the “growing” phenotype, myelinating Schwann cells will de-differentiate to become non-myelinating 
Schwann cells for approximately 6 months following injury until the re-differentiate into myelinating 
phenotype. Non-myelinating Schwann cells feature down-regulation of the genes responsible for 
myelination and an up-regulation of genes that lead to neurotrophic factor and adhesion molecule 
production. This change in phenotype is associated with Schwann cells’ proliferation and with the overall 
effects of providing growth factors locally, influencing immune response, and clearing cellular debris [118]. 
Common treatment methods for Schwann cell-based therapies include their direct transplant and stem cell 
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transplants that then differentiate into Schwann cell-like cells. They also have been combined with 
neuroprotective agents and inhibitory molecules to encourage improved regeneration [118]. 
Nerve guidance conduits seeded with Schwann cells have been developed as an alternative 
treatment to autograft nerve transplants with support given by in vivo studies. Early studies found the 
development of new nerve fascicles at the distal nerve stump following repair with a vein graft NGC seeded 
with Schwann cells producing increased myelin density and average conduction velocity [119]. Barton et 
al.’s study tested a co-transplant of olfactory ensheathing cells and Schwann cells to find that the combined 
transplant yielded better results than when treating with either of the cell types in isolation. Transplanted 
Schwann cells are capable of acting as drug delivery modalities, supplying endogenous neurotrophic factors 
to injury sites with the capacity for the cells to migrate at the site. The secretion of neurotrophic factors and 
cell-adhesion molecules provide a guiding effect for regenerating axons. SCs can be genetically modified 
to secrete viral and non-viral vectors, which have both undergone pre-clinical in vivo studies to determine 
their potential. Designing clinical-grade vectors comes with challenges regarding their clinical safety, 
control, target specificity and resultant immune response, despite the pre-clinical model successes. 
Adenovirus-based gene therapies are the most commonly tested viral vectors with extended release 
duration, the ability to directly or retrogradely transduce neurons, and minimal potential for insertional 
mutagenesis [120]. 
It is important to note that the clinical use of Schwann cells has been limited due to a lack of 
feasibility and commercial viability, supported by an FDA phase 1 clinical trial for the treatment of MS 
which found that there was no evidence supporting the sustained viability of transplanted Schwann cells 
[118]. In an evaluation of the survival of transplanted Schwann cells in vivo, Gambhir et al. used a nucleus-
restricted fluorescent label and co-administered NRG1β, a therapeutic with the potential to drive rapid 
Schwann cells migration, finding improved cell viability [121]. These conflicting studies suggest that more 
research is necessary to determine the effectiveness of transplanting Schwann cells or if using stem cells is 
a valid alternative once the cells differentiate and produce neurotrophic factors. 
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1.5.3.2. Stem Cells 
Stem cells from various origins have been used in peripheral nerve regeneration studies in vitro and 
in vivo as a cell therapy treatment, including embryonic stem cells (ESC), induced pluripotent stem cells 
(iPSC), adult mesenchymal stem cells (MSC), and neural stem cells (NSC). This treatment method employs 
similar mechanisms to stimulate regeneration as the previously mentioned Schwann cell transplants, 
because implanted stem cells are often driven to develop into Schwann cell-like cells that will provide 
neurotrophic factors to the injury site [57]. This promotes the development of a positive microenvironment 
that encourages the survival of neuronal cells and the formation of new nerve cells [122]. 
Transdifferentiation of stem cells into Schwann cell-like cells has been a field of interest for 
researchers, with several techniques showing promising results. Chemical treatments incorporating a 
cocktail of growth factors have shown consistent results in driving stem cells towards such Schwann cell-
like lineages [123-125]. As an alternative to chemical growth factor transdifferentiation, in a 2018 study, 
Manoukian et al. experimented with in vitro electrical stimulation of human MSCs showing positive results 
for morphological and phenotypical changes towards Schwann cell-like or neuronal lineages [126].  
Whether stem cells are transdifferentiated prior to incorporation or not, there are several developed 
techniques for their delivery in vivo. Stem cells can be suspended in a matrix or medium which is then 
microinjected into the nerve endings or around the repair site. Intraneural injections can be traumatic to the 
intra-neural architecture without the ability to predict the distribution of the cells once injected, making this 
an unfavorable method for delivery [127]. Fibrin matrix or hydrogels are often used to suspend the stem 
cells for local delivery. These suspension matrices can be loaded into conduits and are used to repair nerve 
defects by injecting them either into the lumen or the matrix of the conduit [122].  
In a study testing a neurotrophic factor delivery system, Meyer et al. transplanted Schwann cells 
genetically modified to overexpress neurotrophic factors and used NVR-hydrogel-enriched chitosan 
conduits. The NVR-Gel significantly reduced the neuroregenerative effects of the growth factors being 
expressed, impairing axonal outgrowth. Despite these negative findings, the hindrance was overcome when 
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the Schwann cells were engineered to overexpress FGF-218kDa [128]. Conduits the have the cells cultured 
or seeded onto them do not experience the inhibition that cells experience when moving through the 
matrices like hydrogels. The conduits that are commercially available from natural or synthetic materials 
have useful substrates that allow cell adhesion although the degradation profiles for these conduits need to 
be considered in the cell therapy development [127]. Stem cell treatments have been found to promote 
regeneration in the presence and absence of luminal fillers. 
1.6. ANIMAL MODELS AND FUNCTIONAL ASSESSMENTS 
The functional assessment selected to determine recovery status is dependent on the selected animal 
model, the functions that the injured nerve controls, and the desired measurements. The sciatic nerve, the 
leading nerve model, innervates the portion of the musculoskeletal system used for walking as well as fine 
motor functions of the toes, providing distinct biomechanical evidence of nerve injury. To detect sensory 
recovery, nerves require stimulus to provoke the withdrawal reflex response, indicating both sensation 
redevelopment and muscle re-innervation. Outside of function specific testing, studies often perform tests 
to determine the amount of development that has occurred during recovery through histology and 
morphology. 
Early testing included the use of larger animal breeds (non-human primates, dogs, cat, etc.) for 
better translational data, but there has been a significant decrease in their use for ethical and humane reasons 
in the United States [129]. The animal type and nerve selected for induced PNI’s limits the functional 
assessments available for testing. Several of the functional assessments (nerve conduction and muscle 
atrophy studies) can be used universally for nerve function while others are only available for specific 
animals due to size restrictions or are based on certain motor functions (walking gait, vibrissae movement, 
and finger function). Researchers tend to migrate toward rodent models (most popularly, the rat model) as 
the field standard producing comparable data. Despite this, there has been movement toward replacing in 
vivo studies with in vitro models to for animal welfare but are limited due to nerve tissue’s structural 
complexity [130]. 
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1.6.1. Rat Sciatic Nerve Model 
The sciatic nerve in rats is the standard test model for nerve regeneration studies due its relatively 
large size and accessibility, along with dramatic functional deficits that result from its injury permitting 
functional recovery assessment. It stretches from the sciatic notch in the pelvis until it trifurcates mid-thigh 
into the tibial, peroneal, and sural nerves, providing a large enough region to facilitate surgeries [130]. The 
sciatic and following nerves have all been used in detecting leg, foot and toe function for recovery. Changes 
due to defects include changes in paw placement, stepping patterns, gait phases, strength and mobility [131]. 
Studies using larger animal breeds tend toward us of the femoral, tibial and peroneal nerves because these 
animals do not have the same size restriction as rodents while producing comparable defects [129]. 
Standardized functional indices for the sciatic, tibial, and peroneal nerves are commonly used as well as the 
Basso Beattie and Bresnahan (BBB) locomotive rating for assessing mobility.  
1.6.2. Walking Track Analysis and Sciatic Functional Index (SFI) 
For the detection of gross motor function in gait across animal models, walking track analyses are 
used extensively. Earlier methods used for walking track analysis used different colored ink to mark the 
rodent’s foot prints, which were used to measure the print length along with the 1-5 and 2-4 toe spread as 
the rodent walked on a paper path [132]. In recent history, technological advancements have made digital 
walking track analysis possible where software programs have been designed to analyze the forelimb-
hindlimb coordination for rodents and detect movements that cannot be caught visually with static and 
dynamic paw parameters [37]. These tests analyze aspects of the animals’ walking pattern incorporating 
stride length and the area of the paw in the considered factors for determining sciatic nerve injury [133].  
Computerized walking gait systems use a transparent motorized treadmill with ventral high-speed 
video cameras to record normal walking, which is then digitized leading to calculation of a variety of gait 
parameters including the Sciatic Functional Index (SFI) without the high level variability and confounding 
factors affecting manually recorded data [134]. This method can be translated for the tibial and peroneal 
nerves to produce corresponding indices [135, 136]. Arguably the “gold standard” for functional assessment 
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of sciatic nerve damage and repair, the SFI has been well established in literature for a variety of studies 
aimed at peripheral nerve regeneration [80, 110, 137, 138]. To calculate the SFI, the following Equation 1 
must be used, where EPL is the experimental print length, NPL is the normal print length, ETS is the 
experimental toe spread, NTS is the normal toe spread, EIT is the experimental intermediary toe spread, 
and NIT is the normal intermediary toe spread [136]: 
𝑆𝐹𝐼 =  −38.3 × (
𝐸𝑃𝐿−𝑁𝑃𝐿
𝑁𝑃𝐿
) + 109.5 × (
𝐸𝑇𝑆−𝑁𝑇𝑆
𝑁𝑇𝑆
) +  13.3 × (
𝐸𝐼𝑇−𝑁𝐼𝑇
𝑁𝐼𝑇
) − 8.8 (1) 
1.6.3. Basso, Beattie, and Bresnahan (BBB) 
The BBB locomotor rating is a motor coordination index used for open field testing on rodents. 
This system takes into account 10 behavioral categories including limb movement, trunk position, paw 
placement, coordination, toe clearance, predominant paw position, trunk instability, and stepping along 
with the general positioning of the abdomen and the tail using a standardized scoring sheet for observation. 
The BBB scale spans a wide spectrum, ranging from a score of 0, consisting of no observable hindlimb 
movement, to a score of 21, consisting of consistent plantar stepping and coordinated limb movement. 
Relative scoring within these categories makes this method reliable for comparison when done by trained 
examiners. Basso et al. identified the curvilinear relationship between functional motor recovery and tissue 
sparing for spinal cord injuries and further deduced that this technique can be used to accurately predict the 
spared white matter at an injury site for spinal cord injuries [130, 139]. Barbosa et al. later used this method 
for detecting functional recovery from a sciatic nerve injury in rats, to detect sensorimotor function. The 
comparison of BBB scores indicated that the hydrochloric extract treated animals experienced accelerated 
functional recovery [140]. The BBB does not take fine motor function of the paws into consideration like 
the SFI in its inclusion of toe spread and paw area, serving as a fundamental difference between the two, 
along with its more subjective basis of rating. Most nerve regeneration studies use a combination of the 
functional recovery assessments [141, 142], like Mohammadi et al.’s study of thyroid hormone on rats, 
confirming faster and better recovery of axons through BBB and SFI [143].  
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1.6.4. Nerve Conduction Velocity and Compound Motor Action Potential (CMAP) 
A functional assessment measuring the compound motor action potentials (CMAP) requires the 
nerve to be stimulated proximal to the injury site under anesthesia using an electrode needle, recording the 
evoked potential with a microneedle inserted into the muscle and corresponding joint [144-147]. This study 
provides information on the transmission of action potentials resulting in muscle movement, indicating the 
return of motor neuron innervation. For detection of sensory neuron re-innervation, this study can be done 
with the stimulating electrodes placed distal to the injury site and the microneedle electrode proximal [130]. 
Ichihara et al. used these methods to record the distance from the stimulation site and measure the 
amplitudes of action potentials from peak-to-peak to calculate the nerve conduction velocity [144]. This 
method can also be used for large animal models, as seen in its use in a study of ultrasound guided plasma 
rich protein factor’s influence on recovery from a crush injury in an ovine (sheep) model [148]. 
1.7. CLINICAL APPLICATIONS AND COMMERCIALIZED NGCs 
While there have been significant tissue engineering advancements over the past decade using 
nerve guidance conduits (NGC) and pharmaceutical agents, few of these developments have been tested 
clinically. The current standard-of-care for PNIs includes gold standard the autografts, FDA-approved 
hollow conduits, and decellularized nerve allografts [149]. Presently, there is a wide range of conduit 
materials and therapeutics with a variety of mechanisms that have exhibited their ability to enhance nerve 
regeneration and have not been tested clinically. Further in vitro and in vivo studies are needed to determine 
the potential side effects of tissue engineering treatments prior to their clinical debut. The sural nerve is the 
most common nerve used for autograft procedures but, as a sensory nerve, there is limited functional 
recovery developed in the treatment of mixed motor-sensory nerves [150]. Research is needed for treatment 
without limitations or restrictions based on the defect size or the time between the injury and repair [151]. 
Currently there are FDA-approved conduits for treatment of PNI composed of a wide variety of 
biomaterials, both natural and synthetic, with a wide range of diameters, lengths, and properties. Table III 
summarizes some of the popular commercially available FDA-approved conduits.  
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Table III: Commercially available nerve guidance conduits and repair products with associated information and properties. 
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CHAPTER 2: ALIGNED MICROCHANNEL POLYMER-NANOTUBE COMPOSITES FOR 
PERIPHERAL NERVE REGENERATION: SMALL MOLECULE DRUG DELIVERY 
This chapter is adapted from an article published in Journal of Controlled Release, Vol. 296, Manoukian, 
Ohan S., et al. “Aligned microchannel polymer-nanotube composites for peripheral nerve regeneration: 
Small molecule drug delivery.” Copyright Elsevier (2019). https://doi.org/10.1016/j.jconrel.2019.01.013.  
2.1. INTRODUCTION 
Peripheral nerve injury (PNI) often results in a loss of sensory, motor, and autonomic functions in 
the affected region. Moderate and severe PNI is often marred with very slow and frequently incomplete 
regeneration and can cause severe loss of sensory and motor function, where recovery is inversely 
proportional to the severity of damage [14, 152, 153]. Such injuries have a significant, and sometimes 
permanent, impact on patients and their day-to-day activities. Unlike cellular repair in other injuries, the 
wound healing response of the peripheral nerve does not involve mitosis and cellular proliferation [152]. 
In contrast, upon PNI, a calcium-mediated process known as Wallerian degeneration is initiated distal to 
the injury zone, starting with axonal breakdown, as a measure to alleviate abnormal axon regeneration [20]. 
Regeneration at the proximal stump begins within 24-48 hours, as a growth cone protrudes from the axonal 
stump and grows toward the target organ [154], but this endogenous repair usually does not sustain itself 
beyond 12 months [52].   
Axonal regeneration is an extremely slow process that occurs at a rate of ~1mm/day and requiring 
at least 12-18 months for muscle reinnervation and initial functional recovery [155]. However, nerve gaps 
in the peripheral nervous system larger than 5mm often cannot regenerate naturally [156]. In the case of a 
critical-sized nerve defect, where the lesion extends too far away from the proximal end of the intact axon, 
regeneration to the distal stump is vitally slow and there is a great risk of traumatic neuroma formation, 
which not only renders the neuron ineffective, but is often very painful [157]. Those injuries which recover 
spontaneously (neurapraxic lesions) are thought to represent instances in which at least some of axons retain 
continuity through the lesion site [158]. If all axons are transected, then recovery depends on surgical 
intervention [37, 159]. Axonal and myelin sheath degradation stimulate proliferation and migration of 
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Schwann cells and other neuronal support cells to the site of injury, forming conduits which guide 
regenerating axons to their target, known as the bands of Büngner [160, 161]. In addition to acting as a 
conduit, Schwann cells are a source of key neurotrophic factors, which exert trophic influence to which 
regenerating axons preferentially respond to, stimulating axonal regeneration by upregulating neuronal cell 
adhesion molecules and trophic cues [162, 163]. 
Current treatments for PNI depend largely upon surgical intervention, most popularly the use of 
autografts and allografts. These are limited by donor site morbidity and sensory loss, scarring, neuroma 
formation, limited supply, and potential immunosuppression [164]. Typical engineering approaches focus 
on synthetic or biological nerve conduits, however, due to variable, suboptimal outcomes these options are 
not often clinically utilized or used for noncritical small diameter sensory nerves only. Transient electrical 
stimulation has been extensively studied and has been reported to increase the speed of functional recovery 
after crush PNI due to increased nerve conduction. However, critical-sized nerve defects require the use of 
nerve guidance conduits to bridge the gap and implementation of electrical stimulation poses a challenge 
in a clinical setting [165]. 
In an effort to mimic the effects of transient electrical stimulation, namely promotion of nerve 
impulse conduction via a pharmacological approach, the sustained release of a pharmacological agent that 
promotes impulse conduction may aid in regeneration of peripheral nerve following injury. A small-
molecule drug, 4-Aminopyridine (4AP), with a molar mass of 94.11 g/mol is a voltage-gated potassium 
channel blocker and FDA approved in 2010 as AMPYRA® (Acorda Therapeutics, Inc.) for treatment of 
multiple sclerosis (MS). Due to its potassium channel-blocking abilities, it has been shown to prolong nerve 
action potentials and strongly promote neurotransmitter release [166-168]. Furthermore, direct 
administration has shown to enhance both speed and extent of functional recovery, as well as promote 
remyelination, following minor nerve crush injury [158]. However, the use of 4-aminopyridine has never 
been reported for applications in a segmental nerve defect, where there is a physical gap between proximal 
and distal ends of the nerve, or in any sustained-release formulations for such an application. 
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The ability of 4AP to block potassium channels causes delayed repolarization and allows it to 
prolong action potentials and amplify neurotransmitter release within neurons. This serves to potentiate 
electrical performance and is the key factor which contributes to 4AP’s clinical feasibility and utility as a 
therapeutic for MS [169], spinal cord injury [170], myasthenia gravis [171], and Lambert-Eaton syndrome 
[172]. The 4AP-induced blocking of potassium channels also has an effect on Schwann cells, which are 
present on the neurons and which migrate to the site of injury. The reduction of voltage-gated potassium 
channels has been correlated to the onset of myelin formation and developmental myelinogenesis [173, 
174]. As such, a pharmacological reduction of potassium channels may have similar effects, leading to 
substantial myelin differentiation and neurotrophin release. 
A number of natural and synthetic polymers are currently employed in biomedical applications, 
particularly as tissue engineering scaffolds and/or drug delivery systems. Most natural polymers are 
particularly attractive due to their inherent biocompatibility and biodegradability. Chitosan (Cht), the 
partially deacetylated derivative of chitin, is one such natural polymer derived from the shell of shrimp, 
crab, and other crustaceans. As such, it is abundant, affordable, and easy to commercially produce. 
Furthermore, several decades of polymer research have shown chitosan to be biodegradable, biocompatible, 
and possess antimicrobial properties [175-178]. Chitosan and its complexes have been studied for several 
biomedical applications including wound healing [179, 180], drug delivery [181], and implants [182]. These 
include applications related to nerve repair and regeneration [14, 183-185]. However, chitosan often lacks 
appropriate mechanical properties, particularly Young’s modulus, for many biomedical applications. Its 
appeal as a hydrophilic polymer encourages the formation of hydrogels, however those limit the end-
application, not having sufficient structural and mechanical integrity. 
As such, we investigated the use of halloysite nanotubes (HNT) to form a stronger chitosan-HNT 
composite structure. HNT’s have garnered major research attention over the last five years due to their 
nano-nature and intrinsic properties. Halloysite is a naturally-occurring aluminosilicate nanotube and has 
been researched for applications as reinforcements in nanocomposites, where they serve to increase 
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mechanical properties [186]. The neighboring alumina and silica layers, and their waters of hydration, curve 
and form multilayer tubes due to a packing disorder. They possess a hollow lumen (10-150 nm diameter) 
which provides excellent ability to carry, encapsulate, and transport chemical agents [186]. They can be 
effective in controlling the initial burst drug release typical of polymeric matrices and can prolong the 
sustained drug release, which remains a challenge for natural polymer systems. 
In this study, we describe the fabrication, characterization, and testing of a porous chitosan sponge 
conduit scaffold, fortified with HNTs, with aligned micro-channel porosity as a drug delivery system and 
nerve guidance conduit (NGC) to bridge peripheral nerve defects, capable of guiding regenerated axons 
and delivering a sustained release of 4AP to the local target site. 
2.2. MATERIALS AND METHODS 
2.2.1. Materials 
High molecular weight chitosan, halloysite nanotubes, epichlorohydrin, and FITC were purchased 
from Sigma-Aldrich (St. Louis, MO). Glacial acetic acid, sodium hydroxide pellets, phosphate buffered 
saline (PBS), LIVE/DEAD™ Viability/Cytotoxicity Kit, regenerated cellulose dialysis tubing with a 
MWCO of 3,500 Da, Nunc™ Lab-Tek™ II Chamber Slides, 4% Paraformaldehyde solution, Triton™ X-
100, and NucBlue DAPI reagent were all purchased from Fisher Scientific (Fair Lawn, NJ). Normal goat 
serum, anti-NGF antibody (catalog #ab6199), anti-P0/MPZ antibody (catalog #ab61851), anti-BDNF 
antibody (catalog #ab108319), and goat anti-rabbit Texas Red (catalog #ab6719) were purchased from 
Abcam (Cambridge, MA). 4-Aminopyridine (>99%) was purchased from Alomone Labs (Jerusalem, 
Israel). Human Schwann cells and cell media were purchased from Sciencell Research Laboratories Inc. 
(Carlsbad, CA). 
2.2.2. Halloysite Nanotube Drug Loading 
4AP-saturated solution was produced by dissolving 4AP in ultrapure distilled water at a 
concentration of 50 mg/mL at room temperature. Following dissolution, dry HNT was mixed with the 4AP-
saturated solution in a weight ratio of 1:2. To encourage better dispersion and prevent precipitation, 
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ultrasonication was employed for 1 hour. Cyclic vacuum pumping in/out was employed to enhance the 
replacement of air in the HNT’s internal lumen with saturated liquid [187]. Vacuum was applied for 30 
minutes, then the vacuum was broken, allowing 4AP solution to enter the lumen. This vacuum process was 
repeated three times and finally left overnight for higher drug loading. The HNT-4AP powder was separated 
by centrifugation (5000 rpm, 20 minutes) and washed with DI water three times to remove unloaded drug. 
Post-centrifugation, HNT-4AP powder was collected and freeze-dried for 24 hours to obtain dry powder. 
10 mg of dry HNT-4AP powder was weighed and evaluated for drug loading using thermogravimetric 
analysis [186, 187]. 
2.2.3. Fabrication of Composite Nerve Guidance Conduits 
High molecular weight chitosan (Cht) (3.0% w/v) was dissolved in 2% (v/v) acetic acid solution at 
50 °C in a water bath. The chitosan solution was stirred overnight until a homogenous solution was 
obtained. Air remaining in the solution is removed by vacuum pump for 24 hours. Conduits were prepared 
by injecting chitosan solution into custom-made molds of appropriate dimensions. The molds were 
subjected to 1 h of vacuum to remove air bubbles and allow equilibration at room temperature. The 
following unidirectional freezing was performed using a modified version of a published methodology 
[188]. The molds were then placed in insulating Styrofoam containers, such that only the bottom surface 
was exposed. The molds, covered with Styrofoam, were then placed onto the surface of a pre-cooled 
stainless-steel plate submersed in a 5 cm-deep pool of liquid nitrogen. As such, this created a uni-axial 
thermal gradient, which resulted in unidirectional freezing of the Chitosan solution (Figure 6). Samples 
were allowed to freeze for 30-45 min and were then subjected to freeze-drying to create to final structure. 
Random (unaligned) conduits were fabricated by simply freezing the chitosan solution overnight at -80 °C 
prior to freeze-drying. Similarly, samples with HNT and HNT-4AP were fabricated with the addition of 
5.0% (w/w) of dry powder to the stirring chitosan solution. The freezing and lyophilization of HNT-4AP 
conduits was identical to that of neat chitosan conduits. 
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2.2.4. Crosslinking of Composite Conduits 
Freeze-dried chitosan conduits were crosslinked using alkaline epichlorohydrin (ECH). Alkaline 
epichlorohydrin solution (0.01 mol/L ECH) was prepared in NaOH solution (0.067 mol/L) and samples 
were incubated in ECH solution at room temperature for 30 minutes [189, 190]. After this period, the 
samples were rinsed thoroughly with DI water three times to remove unreacted ECH. Samples were then 
vacuum dried to remove residual water. 
2.2.5. Water Absorption (Swelling) 
Crosslinked samples were tested for water absorption properties by soaking samples in 37 °C PBS 
(pH 7.4). Pre-incubation, samples were weighed to obtain initial dry weight. At predetermined timepoints, 
samples were removed from PBS, excess liquid was removed by gently tapping the samples onto Kimwipe 
Figure 6: Simplified schematic of the unidirectional freezing setup which uses a uni-axial thermal gradient to create linear 
formation of ice crystals. (b) The formation of linear ice crystals is shown using the uni-axial thermal gradient setup. (c) 
Simplified schematic illustrating the process of incorporating 4AP drug into Halloysite Nanotubes (HNT) and subsequently 
mixing with chitosan in a custom mold to produce drug-loaded conduits. A photograph of the prototype is shown along with 
representative SEM images of the aligned, porous microstructure. 
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paper and weighed to obtain the wet weight.  The percent water absorption was calculated using the simple 
ratio of weights given in Equation 2, where Wt is the wet weight (g) and W0 is the dry weight (g) prior to 
immersion in PBS [191]. 
𝑊𝑎𝑡𝑒𝑟 𝑎𝑏𝑠𝑜𝑟𝑝𝑡𝑖𝑜𝑛 (%) =  
𝑊𝑡−𝑊0
𝑊0
∗ 100 (2) 
2.2.6. Conduit Porosity 
Porosity of composite structures was calculated using a standard calculation of volume and mass, 
given by Equation 3 [191], where Vm is total volume of samples (cm3), Wm is mass of samples (g), ρ is 
density of chitosan (1.342 g/cm3). For all porosity measurements, samples (n=5) were formed in cylindrical 
molds and measurements of height and diameter were made in order to calculate total volume.  
𝑃𝑜𝑟𝑜𝑠𝑖𝑡𝑦 (%) =  
𝑉𝑚−
𝑊𝑚
𝜌
𝑉𝑚
∗ 100  (3) 
2.2.7. Scanning Electron Microscopy (SEM) Imaging 
Surface morphology of samples was visualized and analyzed using scanning electron microscopy 
(SEM) (JEOL JSM-6335F, JEOL USA, Inc., MA, USA). Samples (n=3 for each formulation) were 
appropriately cut, adhered to carbon tape on SEM stub, and coated with Au/Pd using a Polaron E5100 
sputtering system (Quorum Technologies, East Sussex, UK) for 3 minutes prior to imaging; This achieved 
a conductive layer of approximately 18 nm.  ImageJ (NIH, Rockville, MD) was used to process and analyze 
images. 
2.2.8. In Vitro Degradation 
The degradation of conduit conduits (n=5) was studied in PBS (pH 7.4) and PBS+lysozyme at 37 
°C. Conduits were initially weighed and immersed in PBS solution containing 4 mg/mL lysozyme at 37 °C 
for 12 weeks [192, 193]. Samples were collected after 1, 2, 4, 6, 8, and 12 weeks, washed three times in DI 
to remove ions adsorbed on the surface and freeze-dried. The freeze-dried samples were weighed and the 
36 
 
degradation (mass loss) was calculated using Equation 4 [194], where Mi is the initial weight (g) of the 
conduits prior to immersion and Mf is the final weight (g). 
𝑀𝑎𝑠𝑠 𝑙𝑜𝑠𝑠 (%) =  
𝑀𝑖−𝑀𝑓
𝑀𝑖
∗ 100 (4) 
2.2.9. Mechanical Testing 
Crosslinked neat chitosan (0% HNT) and 5.0% HNT samples (n=6) were tested in the wet state by 
incubating in PBS (pH 7.4) overnight at room temperature prior to testing. Testing was performed on an 
Instron 3300 Single Column Universal Testing System (Instron, Norwood, MA, USA) at a tension rate of 
5 mm/min. The testing yielded both tensile strength and Young’s modulus results of the various samples. 
2.2.10. Crystallinity (X-Ray Diffraction) 
X-Ray diffraction (XRD) studies were performed using a Bruker D2 Phaser (Bruker AXS, 
Madison, WI, USA). XRD patterns for neat chitosan, neat 4AP, HNT-4AP, and composite CHT/HNT-4AP 
structures were recorded. Values were recorded from 5-40° (2θ) at a scanning speed of 0.2 deg/s. Cu-Kα (λ 
1.546 Ǻ) radiation at 40 kV and 30 mA was used as the X-Ray source. 
2.2.11. Thermal Characterizations (DSC and TGA) 
DSC thermograms were obtained for neat chitosan, neat 4AP, HNT-4AP, and composite 
CHT/HNT-4AP samples using a TA Instruments DSC Q100 (TA Instruments, New Castle, DE, USA). 10 
mg of each sample in an aluminum pan was heated from 0-400 °C at a rate of 10 °C/min under 50 mL/min 
nitrogen purge. The DSC data was analyzed using the associated TA Instrument’s Universal Analysis 
software package. Similarly, thermogravimetric analysis (TGA) of aforementioned samples was done using 
a TA Instruments TGA Q-500 (TA Instruments, New Castle, DE, USA). A 10 mg sample in a platinum pan 
was heated from 0-700 °C at a rate of 10 °C/min under nitrogen purge. Thermograms were recorded to 
capture weight loss as a function of increasing temperature.  
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2.2.12. Halloysite Nanotube Distribution, Alignment, and Imaging 
In an effort to qualitatively determine the distribution of HNTs throughout the chitosan polymer 
matrix, HNTSs were loaded with FITC in a similar manner as fully described above. Briefly, FITC was 
dissolved in acetone (1 mg/mL) and following dissolution, dry HNT was mixed with the FITC-saturated 
solution in a weight ratio of 1:2. The FITC-loaded HNTs were then centrifuged, freeze-dried to obtain 
powder, and later applied as 5% to the chitosan solution to create a composite structure. The structures were 
fabricated as described above, and thin circular slices were cut and the FITC-loaded HNTs were imaged 
using confocal microscopy. The images were processed and analyzed for directionality using ImageJ. 
2.2.13. In Vitro Human Schwann Cell Viability 
In order to assess the biocompatibility of chitosan conduits, an in vitro assessment was conducted 
using human Schwann cells at passage two. Cell viability was tested using a technique commonly known 
as live/dead staining, where kits combine fluorescent reagents to yield two-color discrimination of the 
population of live cells (green) from the dead-cell population (red). The LIVE/DEAD™ 
Viability/Cytotoxicity Kit was used and samples for live/dead assay were prepared by following assay 
manufacturer’s instructions. Thereafter, confocal microscopy (Zeiss LSM 880, Carl Zeiss AG, Oberkochen, 
Germany) was performed for imaging. 
Chitosan conduits were prepared as per the aforementioned method and sterilized under ultraviolet 
(UV) light for 1 hour on each side. Post-sterilization, conduits were soaked in appropriate medium for 1 
hour prior to seeding 30,000 cells on top surface in untreated 24-well plates. Cell staining and imaging was 
performed 7 days post-seeding and confocal microscopy was used to obtain Z-stack images of conduits (10 
slices, in 10 µm increments) in order to assess cell penetration within the 3D conduit and overall cell 
viability. Images were analyzed and maximum projection and gradient hyperstacks were created using 
ImageJ (NIH, Bethesda, MD). 
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2.2.14. In Vitro 4AP Drug Release 
For 4AP drug release studies, the following groups were prepared as per aforementioned methods: 
(1) crosslinked composite: Cht+5% HNT-4AP, (2) composite: Cht+5% HNT-4AP, (3) crosslinked Cht+5% 
4AP, (4) Cht+5% 4AP, and (5) HNT-4AP. All groups had a sample size of n=5. Approximately 20±2 mg 
of crosslinked and uncrosslinked samples were taken in regenerated cellulose dialysis tubing with a MWCO 
of 3,500 Da. Each bag was filled with 1 mL PBS, secured on both ends, immersed in 10 mL of PBS, and 
incubated in a 37 °C orbital shaker. For each formulation a sample size of n=5 was used. At various 
predetermined time intervals, 1 mL of the release media was collected and replaced with fresh media. The 
concentration of 4AP in the release media was determined by UV-Vis spectroscopy (Genesys 10S, Thermo 
Fisher Scientific, Waltham, MA, USA) at a λmax of 260 nm using a standard curve previously created for 
4AP in PBS [76, 176, 195]. 
2.2.15. Cell Dose-Response Toxicity and Proliferation 
Human Schwann cells were used for all evaluations of cell dose response to 4AP treatments. 
Schwann cells, purchased frozen at passage one, were expanded to and harvested at passage two, as per the 
manufacturer’s protocols. Cells were cultured on poly-L-lysine coated (2 µg/cm2) tissue culture polystyrene 
(TCPS) well plates in manufacturer’s Schwann cell culture medium comprised of basal media, 
supplemented with 5% fetal bovine serum (FBS), 1% penicillin-streptomycin solution, and 1% Schwann 
cell growth supplement. Cell cultures were maintained in a humidified incubator at 37oC and 5% CO2. 
For evaluation of potential toxicity effects, a dose-response study was performed with human 
Schwann cells using a lactase dehydrogenase (LDH) assay (n=5). The LDH assay is a strongly sensitive 
method for quantifying cytotoxicity, or degree of inhibition of cell growth, resulting from interaction of a 
test material with cells. Human Schwann cells were treated with five, varying doses of 4AP and tested for 
percent LDH leakage after 24 hours in culture [196, 197]. Dose-response studies evaluating Schwann cell 
proliferation were performed using a standard colorimetric MTS assay. A colored formazan product is 
produced by dehydrogenase enzymes in metabolically active cells. An MTS assay of human schwann cells 
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was performed at day 1, 7, 14, and 21 with cells treated with 1, 5, and 10 μg/mL of 4AP, compared to an 
untreated control which received no drug. 
2.2.16. Immunofluorescent Staining and Quantification 
For immunofluorescent staining experiments, human Schwann cells, harvested at passage two, 
were seeded onto poly-L-lysine coated (2 µg/cm2) chamber slide wells at a concentration of 6,000 cells/cm2. 
Cells were initially cultured using aforementioned Schwann cell culture medium, and media was replaced 
with 4AP-media solution (drug media) 24 hours post-seeding. Cells received drug media with 4AP in a 
concentration of 1, 5, or 10 µg/mL. These groups were compared to control groups where cells received 
standard Schwann cell culture media without drug. All cell media was changed every three days for the 
duration of the 14-day study (n=3).  
At 14 days post-seeding, immunofluorescent staining was performed in order to examine the dose-
response changes in Schwann cell proteins and neurotrophic factors, compared to control groups. Briefly, 
samples were washed using PBS (all washes performed in triplicate) to get rid of cell culture medium and 
were subsequently fixed for 30 minutes using 4% paraformaldehyde solution. Following fixation, samples 
were again washed in triplicate. Samples were permeabilized using 0.2% Triton X-100 prepared in PBS for 
10 minutes then washed with PBS. Samples were blocked by incubating with 10% normal goat serum in 
PBST (PBS with 0.1% Tween 20) for 30 minutes at room temperature followed by PBS wash. The primary 
antibodies, anti-NGF (1:200), anti-P0/MPZ (1:200), and anti-BDNF (1:1000) were all diluted to their 
respective ratios in the aforementioned blocking solution and added to each sample. Samples were 
incubated with primary antibody solution overnight at 4°C. The following day samples were washed three 
times with PBS followed by incubation for 1 hr with secondary antibody, Texas Red (goat anti-rabbit) 
diluted 1:2000 in blocking solution, and carefully protected from light. Samples were again washed with 
PBS and DAPI stain was applied prior to imaging using a Zeiss LSM 510 Meta confocal laser scanning 
microscope (Carl Zeiss, Oberkochen, Germany) [77, 176]. 
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The resulting images were processed, analyzed, and quantified using ImageJ. To quantify relative 
NGF, P0, and BDNF fluorescence levels, a single in-focus plane was chosen for imaging. Using ImageJ, 
the area, integrated density, and mean gray value were measured for five independent images per sample, 
along with adjacent background readings. The total corrected cellular fluorescence (TCCF) = integrated 
density – (area of selected region × mean fluorescence of background readings), was calculated [198, 199]. 
This TCCF is presented as relative fluorescence of samples with arbitrary units, displayed as box-plots with 
5-95% confidence intervals. 
2.2.17. Statistical Analysis 
All data is expressed as mean ± standard deviation (mean±s.d.). All results were first evaluated 
using t-tests or one-way/two-way analysis of variation (ANOVA) followed by Dunnett’s multiple 
comparisons test. All statistical analyses were performed with a confidence level of 95% (p<0.05) using 
GraphPad Prism 7 (GraphPad Software, Inc. La Jolla, CA). 
2.3. RESULTS 
2.3.1. Conduit Scaffold Characterization 
The aforementioned method of fabricating porous conduits resulted in highly porous, sponge-like 
scaffolds with specified geometries (Figure 7a). When imaged using SEM, a highly-aligned porous 
microstructure can be seen with microtubule-like pores aligned parallel to the longitudinal section (Figure 
7b). Fenestrations can be seen interconnecting the longitudinally-aligned channels [200, 201]. As a result 
of the unidirectional freezing, and subsequent anisotropic growth of ice crystals, the cross-sectional images 
reveal elliptical forms, rather than symmetrical circles (Figure 7c). This is due to the fact that the cross-
section of cellular ice crystals are not rotationally symmetric, but rather elliptical [200]. Given their 
elliptical geometry, measurements of pore Feret diameter, defined as the longest distance between any two 
points along the particle boundary, also known as the maximum size [202], yielded pores of 59.3±14.2 µm 
(mean±s.d.). These findings are in agreement with previous studies which have investigated the effects of 
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topography on axon regeneration and shown that pores sized 20-60 µm along the longitudinal direction 
were optimal for maximum axon penetration and minimum axon misdirection [201, 203]. 
These aligned and interconnected pores allow for longitudinal and horizontal migration of Schwann 
cells [201], which is critical for successful regeneration of nerve tissue, as well as a large surface area to 
provide local and sustained delivery of pharmacological agent to the site of injury [204]. The distribution 
of HNTs within the polymer matrix showed even distribution of aligned HNTs (Figure 7d). The 
directionality of HNTs was calculated using ImageJ, revealing HNT particles aligned preferentially to 
Figure 7: SEM images showing highly porous channel microstructure of (a) conduit cross sectioned, SB = 1 mm; (b) conduit 
sectioned longitudinally, SB = 100 µm; (c) conduit cross sectioned, SB = 100 µm. A highly linear pore configuration can be 
seen throughout the construct. (d) FITC-loaded HNTs were imaged within the chitosan matrix, showing an even distribution 
throughout the construct. (e) The directionality of HNTs was calculated, showing a highly aligned distribution of HNTs 
resulting from the alignment of the polymer matrix. (f) Human Schwann cells seeded on conduit showed alignment and 
proliferation in the direction of the aligned polymer matrix. (g) The directionality of seeded Schwann cells confirmed an aligned 
distribution of cells on the aligned microchannel conduit. 
42 
 
90.6±16.6° (mean±s.d.)  with a goodness of fit R2 of 0.99 (Figure 7e). The direction of alignment is rather 
arbitrary based on image orientation, however a strong goodness of fit to a particular direction is evidence 
of HNTs preferentially oriented in a particular direction, in this case the direction of polymer alignment 
discussed previously. Similarly, when Schwann cells were cultured on conduits with aligned microchannel 
porosity, they show a clear favorable alignment correlating to the alignment of the polymer matrix (Figure 
7f). The directionality calculations show that cells were aligned to 109.8±15.2° (mean±s.d.) with a goodness 
of fit R2 of 0.97 (Figure 7g).  
2.3.2. Mechanical Properties 
An investigation of the mechanical properties, namely Young’s modulus (modulus of tensile 
elasticity) and tensile strength, of conduits with and without halloysite reinforcement was conducting using 
uniaxial tensile testing. Significant differences (p<0.05) were found for both modulus and tensile strength 
with the addition of halloysite reinforcement. The Young’s modulus was calculated to be 0.13±0.02 and 
0.23±0.07 MPa (mean±s.d.) for random (unaligned) conduits with 0% HNT (no halloysite) and 5% HNT, 
respectively. In contrast, the Young’s modulus for aligned conduits were 0.18±0.02 and 0.33±0.09 MPa 
(mean±s.d.) for aligned conduits with 0% HNT and 5% HNT, respectively (Figure 8). 
Figure 8: Tensile mechanical testing of fabricated nerve guidance conduits, both with aligned pores and random porosity, and 
with and without halloysite reinforcement (labelled 5% HNT and 0% HNT, respectively). Young’s modulus is shown to increase 
in composite samples with 5% HNT as compared to samples with 0% HNT. Alignment of pores was shown to have anisotropic 
mechanical properties, increasing the modulus, particularly for the aligned composite with 5% HNT which showed the greatest 
moduli. Where native peripheral nerve is generally considered to have a Young’s modulus of 0.50 MPa (red line), aligned 
composite conduits showed very similar moduli. *=p<0.05, **=p<0.01, and ***=p<0.001. 
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2.3.3. Water Absorption (Swelling) 
A systematic study was done to assess the optimal crosslinking agent and duration for the fabricated 
conduits. Crosslinking was critical for achieving structural integrity and swelling rates. Uncrosslinked 
samples immersed in PBS showed >10,000% swelling within the initial 10 minutes, where polymer samples 
became gel and could not be measured post-10 minute mark (Figure 9a). Thermal crosslinking resulted in 
decrease of water absorption across all crosslinking durations, however, substantial decreases were not 
achieved as water absorption was still 3000-7000% (Figure 9b). Chemical crosslinking using Sulfuric Acid 
(H2SO4) achieved substantial decreases in water absorption rates, with 60 minute crosslinking duration 
achieving ~400% absorption. However, Sulfuric Acid treatment resulted in a breakdown of the structure’s 
physical integrity, with substantial deterioration of the polymer samples (Figure 9c). Epichlorohydrin 
chemical crosslinking was able to achieve significant decreases in water absorption, particularly, when 
treatment duration was 30, 60, or 120 minutes. Water absorption at the 180-mark was measured to be ~400-
500%, with no structural damage (Figure 9d). As a result, ECH was chosen as the crosslinking method 
moving forward for all conduit fabrication and preparation. 
Figure 9: Water absorption, shown as percent of dry weight, with various crosslinking methods and durations. 
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2.3.4. Crystallinity (X-Ray Diffraction) 
X-Ray Diffraction (XRD) of 4-Aminopyridine showed several sharp peaks, namely at 14.40°, 
18.80°, 24.27°, 24.91°, and 32.57°. The sharp peaks of 4AP observed represent the drug to be crystalline in 
nature. Pristine chitosan does not exhibit any sharp peaks, indicating its amorphous nature (Figure 10a). 
Composite chitosan with 4AP showed a hollow diffused pattern, where no sharp peaks of 4-AP are 
observed, indicating that the crystalline nature of drug has been converted to amorphous during 
complexation. XRD of the HNT-4AP showed peaks due to the crystal nature of 4AP and some diffused 
peaks owing to the HNT (Figure 10b). This indicates that there is no complex formation between HNT and 
4AP, merely a filling of the hollow HNT lumen with condensed drug. These findings confirm that the 
entrapped 4AP is dispersed mono-molecularly in the composite chitosan matrix. 
 
2.3.5. Thermal Analysis 
The DSC spectra of 4-aminopyridine is shown with sharp endothermic peak at 165.00 °C which 
represents the crystalline nature of the drug (Figure 11a). DSC spectra of HNT-4AP did not show any 
endothermic peak. The thermograms of composite chitosan showed a shift in the endothermic peaks from 
the original endothermic peaks of pristine chitosan and 4-AP, that is, from 103.07 °C to 82.88 °C and 165.00 
°C to 136.59 °C, respectively, which confirms the formation of composite chitosan drug complex (Figure 
Figure 10: X-Ray diffraction spectra of 4-Aminopyridine, HNT-4AP, pristine Chitosan, and the composite structure indicating 
various degrees of crystallinity. 
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11b). The shifting of peaks from the higher temperature to lower indicates that the crystalline form of the 
drug is converted into a more amorphous form during complex formation. 
 
2.3.6. Porosity 
As previously detailed, composite conduits yieled pores ranging in diameter from 20-60 µm with an average 
size of 59.3±14.2 µm (mean±s.d.). The porosity of conduit structures was evaluated as per the 
aforementioned Equation (1). The porosity values were calculated as follows: Pristine chitosan 
96.03±0.326%, composite 96.03±0.122%, and crosslinked composite 88.66±0.494% (Figure 12). 
Figure 11: Differential scanning calorimetry spectra of 4-Aminopyridine, HNT-4AP, pristine Chitosan, and the composite 
structure indicating various endothermic transitions. 
Figure 12: Porosity measurements for conduits of various formulation. The addition of HNT resulted in negligible porosity 
change from pristine chitosan. However the effect of crosslinking is seen on the polymer matrix density, as porosity decreases. 
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2.3.7. Drug Loading Efficiency 
Analysis of TGA profiles (Figure 13) indicated that 4AP degrades at 130-160 °C and the peak at 
500 °C indicates the presence of halloysite. At this temperature, halloysite does not fully degrade, but 
undergoes a loss of its hydroxyl group [187]. TGA profile of the halloysite drug composites, HNT-4AP 
(Figure 13b) shows the decomposition peaks for both 4AP and halloysite. The amount of 4AP in the 
composite was quantified as mass lost over the given temperature range and is expressed in percent of the 
total mass of the composite. TGA profiles constructed using the parameters identified from derivative 
curves indicated a 7.69 wt% overall drug loading [187]. It has been commonly established in literature that 
successful drug loading of unmodified HNTs reached 5-10 wt% of the tube weight. Taking the density of 
the organic drug as 1.26 and halloysite 2.53 g/cm3, one could see that this value almost coincides with the 
complete filling of the lumen with condensed drug [186, 205]. 
 
2.3.8. In Vitro Degradation 
The degradation of composite conduits was studied under physiologically-simulated conditions in 
PBS and PBS supplemented with lysozyme. The degradation rate of chitosan by lysozyme is inversely 
related to the molecular weight and degree of crystallinity of the chitosan, and proportionally related to its 
deacetylation [206]. Lysozyme recognizes and digests N-acetyl glucosamine sequences in the chitosan 
molecules, thus digestibility increases with increasing degree of N-acetylation in the polymer chain [207]. 
Following 12 weeks of incubation in PBS and PBS+lysozyme, 83.05±1.01% and 70.99±1.27% weight of 
Figure 13: TGA spectra (a) before and (b) after loading of 4AP into HNT. The modification of HNT loaded with 4AP (b) is 
shown as the TGA curve shows decomposition peaks for both 4AP and halloysite. The amount of 4AP loaded into HNT was 
quantified as mass lost over the given temperature range corresponding to the decomposition of 4AP and is expressed as the 
percent of total mass of HNT-4AP. (c) Pristine chitosan and composite Cht/HNT-4AP. 
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samples remained (mean±s.d.), respectively (Figure 14a). Inversely, this resulted in 16.95±1.01% and 
29.01±1.27% weight loss, respectively. Weight loss in PBS+lysozyme at weeks 2, 4, 6, 8, and 12 were all 
statistically significant compared to that of in PBS. To supplement degradation data, samples subjected to 
PBS+lysozyme were collected at various timepoints and imaged using SEM (Figure 14b). Microscopy 
images show a consistent breakdown of the polymer microstructure, with fragmenting, cracking, and 
deterioration gradually increasing in relation the timepoint. 
 
2.3.9. In Vitro Drug Release 
Drug release from a variety of samples was tested in PBS (pH 7.4) at 37 °C. Loaded HNTs showed 
a sustained release of 4AP within 6 h (Figure 15b). When drug-loaded HNTs were incorporated into the 
chitosan polymer matrix (composite), sustained drug release was shown to be extended, with 94.68±3.62% 
of drug being released within 168 h (7 days) (Figure 15c). This release was shown to be in stark contrast 
to that of the release of 4AP from chitosan polymer conduits without the incorporation of halloysite. In this 
case, where 4AP is simply mixed into the chitosan solution prior to fabrication, a 97.84±3.05% release was 
shown within 0.5 h (mean±s.d.). When this formulation, excluding halloysite, was crosslinked, a 
Figure 14: (a) Degradation of crosslinked composite Cht/HNT-4AP samples in PBS pH 7.4 (black) and PBS with 4mg/mL 
lysozyme (red) (n=3 samples/timepoint, mean±s.d.). Degradation represented by the weight (%) of polymer remaining. *=p<0.05 
vs PBS, **=p<0.01 vs PBS, and ***=p<0.001 vs PBS. (b) Representative SEM images showing crosslinked composite samples 
at various timepoints during degradation in PBS+lysozyme. 
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58.19±2.79% release was shown within 7 days. Lastly, formulations of crosslinked composite conduits, 
where 4AP-loaded HNT was incorporated into chitosan conduits and the resultant conduit was crosslinked, 
showed the longest sustained release of 4AP with 30.11±2.02% release within 7 days. No significant 
differences in drug release properties were noted when drug-loaded chitosan conduits were exposed to UV 
during the process of sterilization. The structure of 4-AP released from conduits remained intact as 
evidenced through UV-spectroscopy and bioactivity. 
 
Figure 15d illustrates the effect of the formulations on the early release of 4AP, focusing on the 
burst release, quantified as the percent cumulative drug release within the first 1 h. Drug-loaded halloysite 
(HNT-4AP) samples showed 88.20±6.62%, composite conduits showed 47.27±2.71%, crosslinked 
Cht/4AP conduits (no halloysite) showed 28.67±0.91%, and lastly crosslinked composite conduits showed 
the lowest burst release with 20.03±1.57% drug release within the first 1 h (mean±s.d.). Uncrosslinked 
Figure 15: (a) Schematic of 4AP drug loading into HNT, followed by sustained release of drug from lumen.  (b) Cumulative 
release of 4AP from halloysite nanotubes; (c) cumulative release of 4AP from Cht (black diamond), crosslinked Cht (blue 
square), composite Cht/HNT-4AP (red circle), and crosslinked composite Cht/HNT-4AP (orange triangle) (n=5 samples/group, 
mean±s.d.). (d) Burst release of 4AP from samples, where burst release is quantified as percent cumulative drug release within 
the first 1 h (n=5 samples/group, mean±s.d.). **=p<0.01, ****=p<0.0001. 
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samples of Cht/4AP which did not include halloysite were excluded from the burst release quantification 
as nearly 100% of drug was released in less than 1 h. Thus, according to the data representation, this would 
quantify as 100% burst release. 
The drug release results from tested formulations were fit to various release kinetic models 
including Zero Order, First Order, Higuchi, and Korsmeyer-Peppas (K-P) (Table IV). In the K-P equation, 
the n value is the release exponent that indicates the mechanism of drug release. All three samples showed 
an n<0.5, indicating quasi-Fickian diffusion of drug from the matrix [208], suggesting partial diffusion as 
the drug release kinetic. All four models show an interesting trend for the diffusion rate constant, k, where 
the Composite formulation showed the largest k value, crosslinked (CL) Cht/4AP showed the second 
largest, and CL Composite showed the lowest. Thus, calculations from all four models agree that 4AP 
release from a CL Composite Cht/4AP-HNT matrix was slightly slower than release from a CL Cht/4AP 
matrix, which was in turn, slightly slower than release from a Composite Cht/4AP-HNT. These results are 
also in agreement with the cumulative drug release plot discussed earlier in Figure 15.  
 
2.3.10. Human Schwann Cell Studies 
In an effort to elucidate the effects of 4AP on physiologically-relevant cells, human Schwann cells 
were tested for dose-dependent responses to 4AP with regards to toxicity, proliferation, as well as 
expression of neurotrophic factors and proteins. The LDH toxicity assay, where the loss of intracellular 
Table IV: Cumulative 4AP release data from respective samples fit to the Zero-order, First-order, Higuchi, and Korsmeyer-
Peppas drug release models. 
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LDH and its release (leakage) into the culture medium is an indicator of irreversible cell death due to cell 
membrane damage [209], showed no statistical differences in LDH leakage between any of the 4AP 
treatment groups and the control group, which received no drug, indicating no cytotoxicity caused by the 
presence of varying doses of 4AP (Figure 16a). When analyzed for cell proliferation (Figure 16b), MTS 
assay of 4AP-treated Schwann cells cultured on TCPS for 1, 7, 14, and 21 days revealed conclusive dose-
dependent inhibition, which is in agreement with previous literature [210]. 
 
MTS assay in conjunction with live/dead cell staining techniques were employed to study the 
viability, proliferation, and infiltration of Schwann cells cultured on 3D composite conduits. Over the 
Figure 16: (a) Lactase dehydrogenase (LDH) leakage cytotoxicity assay testing various doses of 4AP treatment on human 
Schwann cells in culture. ns=no significance. (b) MTS assay of human Schwann cells cultured on TCPS with no drug (control) 
or 1, 5, and 10 µg/mL of 4AP for up to 21 days.  *=p<0.05 vs control, ***=p<0.001 vs control, and ****=p<0.0001 vs control. 
(c) MTS assay of human Schwann cells cultured on composite conduits for 21 days. **=p<0.01 vs day 1. (d) Human Schwann 
cells cultured on composite conduits and stained using live/dead cell staining. A Z-stack projection of 10 confocal microscopy 
images, each 10µm deep, is shown (i) and the same image is shown pseudo-colored for cell z-position using a color-depth 
gradient (ii). 
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course of 21 days, MTS assay of human Schwann cells seeded onto 3D composite conduits showed 
increases in cell number with significant proliferation by day 14 and day 21 (Figure 16c). Cell growth and 
proliferation over the 21-day period confirms the biocompatibility of the chitosan-based composite conduit 
system, as well as the composite polymer’s ability to facilitate cell adhesion and proliferation. Given the 
3D nature of the composite conduit, beyond cell adhesion and proliferation, cell infiltration into and within 
the 3D architecture was examined. At day 14, live/dead staining was employed to samples seeded with 
human Schwann cells. Z-stack images were taken at 10 µm slices and the composite images were projected 
and thresholded using a color-depth gradient (Figure 16d). Cell infiltration can be seen throughout the 
entire 100 µm projection with the majority of cells infiltrating 50-80 µm deep. 
Schwann cell neurotrophic factor and protein expression was also investigated as a measure of 
dose-response to 4AP (Figure 17). Human Schwann cells cultured for 14 days with varying treatments of 
4AP were subjected to immunofluorescent staining to assess the expression of three markers of interest: 
nerve growth factor (NGF), myelin protein zero (P0), and brain-derived neurotrophic factor (BDNF). 
Schwann cells were shown to exhibit dose-dependent increases in the expression of all three markers, 
compared to control groups, which received no drug. The dose-dependent increases in NGF, P0, and BDNF 
expression were shown qualitatively via immunofluorescent staining, and calculated as a quantification of 
immunofluorescent staining, expressed as relative fluorescence (Figure 17b). NGF and P0 expression 
showed statistically-significant increases in both 5 and 10 µg/mL 4AP-treatment groups, while BDNF 
expression increases were only significant in the 10 µg/mL treatment group, when compared to no-drug 
control groups. When treated with 10 µg/mL 4AP, NGF, P0, and BDNF showed 128.58±0.57%, 
310.75±11.92%, and 170.94±4.43% increases over no-drug control groups, respectively. 
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2.4. DISCUSSION 
The aforementioned fabrication method for polymeric nerve guidance conduit represents a 
straightforward method for achieving a tubular structure with aligned microchannel porosity for successful 
nerve regeneration. The use of the chitosan polymer not only grants natural biodegradability and 
Figure 17: (a) In vitro immunofluorescent staining images showing human Schwann cells stained for NGF, P0, and BDNF 
(all stained red, respectively by row) in a dose response study to 4AP drug treatment. Control groups, which received media 
without drug, were compared to 1, 5, and 10 µg/mL drug media solutions, respectively by column. SB=10µm. (b) Quantification 
of immunofluorescent staining of NGF, P0, and BDNF (left to right, respectively). The intensity of staining obtained with each 
antibody was measured and displayed as box-plots with 5 to 95% confidence intervals (n=5 images/group). *=p<0.05 vs control, 
***=p<0.001 vs control, and ****=p<0.0001 vs control. 
53 
 
biocompatibility, but also has a broad antimicrobial spectrum to which gram-negative, gram-positive 
bacteria, and fungi are highly susceptible [211]. In addition to its alignment, the composite system’s 
incorporation of aluminosilicate halloysite nanotubes, which serve as an excellent drug-carrier given their 
hollow lumen, represents a highly effective method for the incorporation of small-molecule drug, in 
addition to mechanical benefits. The calculated HNT drug loading of 7.686% was well within the published 
range of 5-10 wt% of the tube weight [186, 205], confirming the complete filling of the tubes with 
condensed drug. Furthermore, silica-based scaffolds have been found to be effective for regeneration of 
soft tissues. Though the exact mechanism is unknown, it is believed that the silicate ions stimulate specific 
pathways responsible for the regeneration process [212].  
A successful nerve guidance conduit should have a Young’s modulus similar to that of native nerve 
tissues to provide sufficient strength and flexibility to be implanted and sutured during implantation, and to 
resist in vivo physiological loading and mechanical mismatch during nerve regeneration [213]. Although 
variations exist, it is generally accepted that Young’s modulus of peripheral nerve, in the longitudinal 
direction, is in the range of 0.50 MPa [214]. In addition to its benefits as an excellent drug-release vehicle, 
the developed composite conduit’s inclusion of halloysite nanotubes is an effective method to achieve 
tunable mechanical properties. Conduits with 5% HNT were shown to have a mean Young’s modulus of 
0.33±0.09 MPa, very similar to that of native nerve. The increase in Young’s modulus, with the increasing 
contents of HNT, are in agreement with other reports in literature [215, 216]. It is also important to note 
that no significant differences in tensile properties were noted when chitosan conduits were exposed to UV 
during the process of sterilization.   
The composite, when processed via freeze-drying, resulted in a highly-porous, foam-like structure 
well-suited for many tissue engineering and regenerative medicine applications. Prior to freeze-drying, 
utilization of the unidirectional freezing technique resulted in consistent, longitudinally-aligned pores 
clearly visible in SEM images. The alignment of the chitosan polymer, and subsequently the halloysite 
nanotube fillers, resulted in mechanically anisotropic properties, preferential to the aligned longitudinal 
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orientation. This is similar to the anisotropic structure of natural nerves, but extends also to muscles, 
tendons, blood vessels, and ligaments, which all have anisotropic mechanical properties [217, 218]. 
Furthermore, anisotropic pore structures have been correlated to excellent cell penetration, where highly 
aligned and porous scaffolds present significant contact guidance cues which promote cell motility within 
the network [219] – all of which are significant advantages with regards to peripheral nerve regeneration. 
This was all evident in the seeding of human Schwann cells on the aligned microchannel conduits, where 
directionality testing confirmed Schwann cell alignment correlating to the polymer alignment. 
Longitudinally-aligned pores within the conduit may serve as axonal tracts and provide 
directionality to the regenerating axon, in addition to providing increased surface area as compared to 
traditional tubular constructs. Given the hydrogel nature of the processed material, chemical crosslinking 
was necessary to stabilize the structure’s integrity in aqueous environments. As an alternative to the most 
commonly used chitosan crosslinking agent, glutaraldehyde [220], which has been shown to be an irritant 
with known toxicity [221], epichlorohydrin was successfully used to crosslink the chitosan-based structure 
and stabilize its water absorption in aqueous conditions. 
According to the pathophysiology of peripheral nerve injury and repair, the first 7-21 days offer 
the greatest potential for facilitated regeneration as this is the period of Wallerian degeneration, cell 
recruitment, and the beginning of axonal regeneration. Release of 4AP using a hydrophilic polymeric nerve 
grafts is challenging. Many such scaffold formulations in our preliminary work released significant amount 
of 4AP (>75%) in the first 24 hours (data not shown). The primary purpose of this study was to solve this 
release problem along with scaffold suturability and its retention under animal leg movement at the defect 
site. 4-Aminopyridine release from fabricated conduits was shown to be dependent on the incorporation of 
halloysite nanotubes as well as the structure’s crosslinking. Release of water-soluble drugs from natural 
polymeric matrices is often quick, while the release of small-molecule drugs is considered rapid; This was 
observed in samples excluding HNTs and crosslinking. 4AP-loaded HNTs showed a sustained release of 
drug within 6 h, in agreement with drug-release values from HNTs previously reported in literature [186, 
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205]. Crosslinking was shown to have a profound effect on sustained drug release, with the crosslinked 
composite structure containing chitosan and 4AP-loaded HNTs showed the slowest release. As such, the 
tunability of fabricated conduit system’s drug-loading and drug release characteristics are highlighted, with 
optimized conduits releasing 4AP from well over seven days.  
4AP treatment of human Schwann cells resulted in significant, dose-dependent upregulation of 
critical trophic factors, namely nerve growth factor (NGF), myelin protein zero (P0), and brain derived 
neurotrophic factor (BDNF), as shown by the immunofluorescent staining images and quantification of 
relative fluorescence. NGF is a neurotrophic factor expressed by migrating Schwann cells in developing or 
regenerating peripheral nerves and has been shown to stimulate the regeneration of axons along with BDNF 
[222, 223]. BDNF is a neurotrophin which has been shown to enhance peripheral nerve system myelination 
[224] and be required for peripheral nerve regeneration and remyelination after injury; studies show 
Schwann cells may contribute as the primary source of BDNF during regeneration [225]. Lastly, P0 is a 
major myelin protein critical in the development of myelin, which sheathes axons and acts as an electrical 
insulator, greatly speeding up action potential conduction. As such, all three factors are critically important 
to healthy regenerating nerves and their upregulation may be the key to more efficient and effective nerve 
regeneration. The MTS cell proliferation assay determined significant decreases in human Schwann cell 
proliferation correlated to dose-dependent 4AP treatment. This 4AP-triggered decrease in proliferation 
corresponds to an increase in myelin differentiation and upregulation of neurotrophins and proteins, 
complimenting the aforementioned immunostaining data. These results are strongly in agreement with 
previous studies, which report that proliferation and myelin differentiation appear to represent two 
incompatible developmental possibilities, both in vivo and in vitro [226, 227]. 
2.5. CONCLUSION 
The developed polymer-nanotube composite drug delivery conduit demonstrates high potential for 
facilitating peripheral nerve regeneration. As an alternative to the conduction effects of electrical 
stimulation, we showed the design and optimization of a nerve guidance conduit with aligned 
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microchannels for the sustained release of a small-molecule drug that promotes nerve impulse conduction. 
A critical challenge is the sustained release of small drug molecules using hydrophilic polymers, due to 
their faster diffusion rates. We successfully demonstrated the sustained release of 4-Aminopyridine as a 
growth factor alternative to enhance the rate of nerve regeneration. The composite conduit released one 
third of the encapsulated 4AP in the first 7 days and the release was shown to be quasi-Fickian diffusion. 
In vitro studies confirmed the beneficial effects of 4AP, increasing expression of key proteins such as nerve 
growth factor, myelin protein zero and brain derived neurotrophic factor in human Schwann cells.  
Future in vivo studies will investigate the effects of the designed nerve guidance conduit in 
combination with 4AP in a critical-sized 15-mm sciatic nerve defect in a rat model over a period of 8 weeks. 
Nerve repair and regeneration will be benchmarked against appropriate controls including the nerve 
autograft (reversed nerve) and the neat conduit (no drug) in terms of quality of tissue healing (histology), 
myelin formation (microscopy), and functionality assessment via walking track analysis. We hypothesize 
that drug-eluting conduits with aligned microchannels will enhance the rate of nerve regeneration, superior 
to control conduit groups, and comparable to the autograft repair. These nerve guidance conduits and 4AP 
sustained delivery may serve as an attractive strategy for nerve repair and regeneration. 
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CHAPTER 3: BIOPOLYMER-NANOTUBE NERVE GUIDANCE CONDUIT DRUG DELIVERY 
FOR PERIPHERAL NERVE REGENERATION: IN VIVO ASSESSMENT 
3.1. INTRODUCTION 
In our previous work we described the fabrication and characterization of a chitosan-based nerve 
guidance conduit scaffold doped with halloysite nanotubes (HNT), a naturally derived dioctahedral 
aluminosilicate clay mineral [69]. These NGCs were fabricated using a unique process for unidirectional 
freezing, resulting in the formation of longitudinally aligned microchannel porosity throughout the tubular 
construct. The advantage of such aligned porosity is simply to influence physical cues and directionality 
for guided axon growth and more efficacious regeneration of nerves. Further, it was used as a drug delivery 
vehicle for the sustained delivery of the FDA-approved small-molecule drug 4-Aminopyridine (4AP), a 
voltage-gated potassium channel blocker, which prolongs action potentials and amplifies neurotransmitter 
release within neurons and Schwann cells for greater nerve regeneration. To our knowledge, this was the 
first use of this drug for in a sustained-release formulation for applications in segmental nerve defects, in 
particular for critical-sized defects [69]. Its successes were shown in vitro as well as in a preliminary in vivo 
study, where the aligned microchannel NGC was implanted into a critical-sized (15 mm) rat sciatic nerve 
defect and showed optimistic signs of nerve healing. 
In an effort to further advance the field of NGC-based nerve regeneration, in this study we describe 
the full in vivo investigation of the previously developed drug delivery NGC. A critical-sized, 15 mm, 
sciatic nerve defect was created in Wistar rats, where the defect was bridged with the 4AP drug-loaded 
conduits and compared to control groups, including the gold-standard autograft, as well as a non-drug-
loaded conduit. The effects of repair and regeneration were evaluated using a large battery of tests and 
assessments including electron microscopy, various histology techniques, and walking track analysis for 
functional motor recovery. The results of functional walking track analysis, morphometric evaluations of 
myelin development, and histological assessments of various markers confirmed the equivalency of 
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implanted drug-conduits repair to autograft control treatments, with potentially transformative implications 
of the fields of regenerative medicine and peripheral nerve repair, regeneration, and engineering. 
3.2. MATERIALS AND METHODS 
3.2.1. Materials 
Chitosan (high molecular weight), halloysite nanotubes, and epichlorohydrin were purchased from 
Sigma-Aldrich (St. Louis, MO). Glacial acetic acid, phosphate buffered saline (PBS) were purchased from 
Fisher Scientific (Fair Lawn, NJ). 4-Aminopyridine (>99%) was purchased from Alomone Labs 
(Jerusalem, Israel). S100B antibody was purchased from Invitrogen (Grand Island, NY). Neurofilament-H 
was purchased from Cell Signaling Technology (Beverly, MA). All surgical tools were purchased from 
Fine Science Tools (Foster City, CA). Neutral buffered formalin, sodium hydroxide pellets, and Vicryl® 
suture were purchased from Fisher Scientific Company (Suwannee, GA). Nylon monofilament suture was 
purchased from McKesson Medical Surgical (Cheshire, CT). Ultrapure water was used from Millipore 
MilliQ system (EMD Millipore, Burlington, MA). 
3.2.2. Drug Loading and Conduit Fabrication 
Drug loading of 4AP into halloysite nanotubes was achieved following the previously detailed 
methodology. Similarly, the fabrication and unidirectional freezing of conduits follows the aforementioned 
methodology. 
3.2.3. Scanning Electron Microscopy (SEM) Imaging 
Images of the conduit surface architecture and microstructure were captured using a JEOL JSM-
6335F scanning electron microscopy (SEM) (JEOL USA, Inc., MA, USA). Samples cut and attached to 
SEM stubs were coated with Au/Pd using a Polaron E5100 sputtering system (Quorum Technologies, East 
Sussex, UK) for 3 minutes prior to imaging, achieving a conductive layer of approximately 18 nm. 
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3.2.4. Animal Subjects 
Forty (40) female Wistar rats (Charles River Laboratories, Wilmington, MA) weighing 
approximately 200 g were randomly divided into four groups: sham (control), autograft repair, conduit 
repair, and drug-conduit repair. All animals were housed in pairs with free access to food and drinking 
water in a temperature-controlled room with a 12-hour light-dark cycle. All animals were allowed to 
acclimate to housing conditions for at least one week prior to surgery. All animals were maintained and 
cared for according to methods approved by the Institutional Animal Care and Use Committee (IACUC) at 
the University of Connecticut. 
3.2.5. Surgical Procedure 
Animals were anesthetized by inhalation of 2.5% isoflurane carried in medical-grade oxygen to 
induce and maintain a surgical anesthetic plane. The right hind leg was shaved and cleaned using betadine 
and isopropyl alcohol. Body temperature was maintained at approximately 37 °C by placing the animal on 
a surgical warming pad. All surgical procedures were conducted under aseptic conditions using sterile tools. 
A 30 mm incision was made parallel to the femoral axis and the right sciatic nerve was exposed through a 
gluteal muscle splitting incision (Figure 18). The sciatic nerve was carefully dissected free of surrounding 
tissues and a 15 mm nerve segment was sharply transected and removed. For conduit and drug-conduit 
groups, a 20 mm conduit was secured to the proximal and distal stumps using 8-0 Nylon monofilament 
suture (Ethicon Inc., Somerville, NJ), with approximately 2.5 mm of nerve stump inside the conduit. For 
autograft groups, the transected nerve segment was reversed and repaired using 8-0 Nylon monofilament 
sutures. The muscle and skin incisions were closed with 5-0 Vicryl® suture (Ethicon Inc., Somerville, NJ). 
In sham-operated animals the sciatic nerve was surgically exposed, as mentioned above, without any injury 
to the nerve. Pain was managed using a multi-modal analgesic approach with injections of Buprenorphine 
every 12-18 h for two days post-operative and injections of Meloxicam every 24 h for three days post-
operative. A saturated solution (1.3%) of aqueous picric acid (2,4,6-trinitrophenol, Sigma-Aldrich Co., St. 
Louis, MO) was applied to the denervated foot immediately after surgery, and twice a week for a month, 
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to deter scratching and biting [228, 229]. At eight weeks post-operative, animals were euthanized by CO2 
asphyxiation. 
  
3.2.6. Walking Track Analysis and Sciatic Functional Index 
Walking track analysis was performed with the DigiGait (Mouse Specifics, Inc., Framingham, MA) 
imaging and analysis system to assess functional recovery following sciatic nerve transection and repair. 
The DigiGait system uses unique ventral plane video imaging to generate computerized paw prints while 
the animal walks on a speed-controlled motorized treadmill belt (Figure 19a). The dynamic gait signal is 
corrected for optimizing signal-to-noise ratio and digitized to analyze and define a wide variety of gait 
Figure 18: Wistar rat critical-size sciatic nerve transection surgery with repair using a composite conduit. (a) A 30 mm incision 
was made parallel to the femoral axis and the right sciatic nerve was exposed through a gluteal muscle splitting incision. (b) A 
15 mm (critical-size) segment of nerve was measured, sharply transected, and removed creating a segmental defect. (c) Top: 
The transected 15 mm sciatic nerve segment. Bottom: The conduit is shown pre-implantation, measuring 20 mm long with a 5 
mm diameter. (d) A 20 mm sterile conduit is sutured to proximal and distal ends of the nerve. (e, f) The gluteal muscle and skin 
incisions, respectively, are sutured closed and the incision site is cleaned. 
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parameters, including sciatic functional index (SFI), paw area, and stance and stride information (Figure 
19b). 
 
In order to assess the functional recovery of sciatic nerve damage and repair, the SFI has been well 
established in literature for a variety of studies aimed at peripheral nerve regeneration [80, 110, 137, 138]. 
The SFI is determined by comparing the geometric representation of the affected hind paw from an injured 
rat, and comparing it to the contralateral paw. To calculate the SFI, Equation 5 is used, where EPL is the 
experimental print length, NPL is the normal print length, ETS is the experimental toe spread, NTS is the 
normal toe spread, EIT is the experimental intermediary toe spread, and NIT is the normal intermediary toe 
spread (Figure 19c) [136]: 
𝑆𝐹𝐼 =  −38.3 × (
𝐸𝑃𝐿−𝑁𝑃𝐿
𝑁𝑃𝐿
) + 109.5 × (
𝐸𝑇𝑆−𝑁𝑇𝑆
𝑁𝑇𝑆
) +  13.3 × (
𝐸𝐼𝑇−𝑁𝐼𝑇
𝑁𝐼𝑇
) − 8.8 (5) 
Figure 19: The DigiGait automated treadmill system performs walking track analysis to quantify differences associated with 
injury severity. (a) A surgically-operated Wistar rat walking on the enclosed treadmill within the DigiGait system. (b) A ventral 
high-speed camera records walking and software digitizes the footprints  in preparation for walking track analysis. (c) 
Differences in several animal paw measurements can differentiate between normal (left; green) and injured (right; red) paws. 
Measurements such as inter-toe (IT, 2-4, distance), toe spread (TS, 1-5, spread), and paw length (PL) are used to calculate 
values such as the sciatic functional index (SFI). 
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Animals were individually placed on the DigiGait treadmill several times to acclimate them with 
the apparatus prior to surgery. Baseline DigiGait data was collected for all animals prior to surgery. 
Following surgery, animals were tested on the DigiGait treadmill every two weeks for eight weeks using 
an optimal speed of ~20 cm/s. Data was saved when animals walked consistently for at least 5 seconds, 
resulting in ~15 complete strides. Animals were then returned to their paired housing cages. 
3.2.7. Transmission Electron Microscopy (TEM) 
Axonal regeneration was investigated by transmission electron microscopy (TEM, HITACHI H -
7650) in the middle regions of the regenerated sciatic nerve. Samples were fixed in 2.5% glutaraldehyde in 
0.1 M phosphate buffer (pH 7.4) for 4 hours at room temperature, then overnight at 4 °C. Samples were 
post-fixed with 1% osmium tetroxide, dehydrated, and embedded using Poly/Bed 812 embedding kit 
(Polysciences Inc., Warrington, PA). Ultrathin sections of 70 nm were cut, stained with uranyl acetate and 
lead citrate, and then examined under a transmission electron microscope. The axon diameter, myelinated 
nerve fiber diameter, and thickness of myelin sheath was evaluated using ImageJ software. For each 
specimen, three images were taken. The G-ratio was calculated according to Equation 6, where Do is the 
outer diameter of the corresponding fiber and Di is the inner axon diameter: 
𝐺𝑟𝑎𝑡𝑖𝑜 =
𝐷𝑖
𝐷𝑜
⁄  (6) 
3.2.8. Histological Evaluation 
Post-euthanasia, the right sciatic nerve was harvested and washed with PBS before being 
transferred to a histological container filled with 10% neutral buffered formalin and fixed at 4 °C overnight. 
Samples were then washed with PBS and transferred to 70% ethanol prior to embedding. Samples (n=3) 
were embedded in paraffin and the middle region of the regenerated nerve (center of the conduit or 
autograft) was cut to approximately 5 µm thick slices in preparation for histological assessments. Following 
standard protocols, hematoxylin and eosin (H&E) and Luxol Fast Blue (LFB) staining was performed, for 
myelin identification, on sectioned slices of sham-operated and repaired nerves. Similarly, 
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immunohistochemistry staining was performed for S100 and Neurofilament-H (NF-H, NF200) markers. 
Histology slides were imaged using an Aperio CS2 high-resolution digital slide scanner (Leica Biosystems 
Inc., Buffalo Grove, IL) and all quantification was performed using ImageJ software using a minimum of 
5 images per group. Liver tissues were also harvested, fixed, and stained for H&E in order to assess any 
potential accumulation and toxicity of HNTs in the rat liver. 
3.2.9. Data Presentation and Statistical Analysis 
All data were analyzed using Microsoft Excel and GraphPad Prism 7 (GraphPad Software, Inc. La 
Jolla, CA). Data  were analyzed via one-way analysis of variation (ANOVA) with Tukey’s posthoc 
corrections for multiple comparisons and reported as mean ± standard deviation (SD) with the exception of 
gait data. Gait data, excluding SFI, are expressed as a ratio between the ipsilateral (right) hind paw and 
contralateral (left) hind paw times 100% and reported as mean ± standard-error-of the-mean (SEM). Gait 
data were analyzed via two-way repeated measures ANOVA (time x group) with Tukey’s posthoc 
corrections for multiple comparisons tests as appropriate. All statistical analyses were performed with a 
confidence level of 95% (α=0.05) using GraphPad Prism 7. 
3.3. RESULTS 
3.3.1. Surface Characterization of Nerve Guidance Conduits 
The surface morphology of conduits with aligned microchannels was imaged and observed using 
SEM. Conduits showed ultra-porous microstructures with elliptical pores with an average size of 59.3±14.2 
μm in diameter (mean±SD) (Figure 20a). The elliptical geometry is an expected result of the anisotropic 
growth of ice crystals during the unidirectional freezing process, and is explained in our previous 
publication. SEM images confirm highly-aligned porosity in the form of longitudinal microchannels, with 
fenestrations interconnecting the channels (Figure 20b). Topographically, the microstructure and 
architectural environment of the conduits are within range for what has been shown to be optimal for 
maximum axon penetration and minimum axon misdirection [201, 203]. 
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3.3.2. Animal Surgeries   
Drug-loaded conduits were tested against non-drug (neat) conduits and autograft repairs, in a 15 
mm critical-sized Wistar rat sciatic nerve model. Autograft repair animals as well as sham-operated animals 
served as controls. Post-surgery, there were no obvious signs of systemic or regional inflammation and no 
surgical complications were reported with all animals surviving surgery.  
One noteworthy complication was autotomy or automutilation by the rats. This is a well-described 
phenomenon of the rat sciatic nerve model where severing and resection of the sciatic nerve results in 
numbness of the foot and the rats often chew off the toes of their denervated foot, thus preventing 
meaningful walking track data [229-231]. This autotomy behavior is postulated to be associated with 
parathesias, similar to phantom limb pain [231], and has been historically shown to affect up to 50 and 
100% of rats undergoing sciatic nerve transection, dependent on strain [232]. Unfortunately, despite the 
well-established literary nature of autotomy in rat sciatic nerve models, this complication is often not 
declared in nerve regeneration studies. For the purposes of our study all animals were intensively monitored 
and examined for signs of autotomy. Rats with severe wounds were excluded from the study. 
Figure 20: Scanning electron microscopy (SEM) images of fabricated nerve guidance conduits (NGCs) in (a) cross section (Size 
bar=1 mm) and (b) longitudinal (Size bar=100 μm). The highly porous microstructure is shown with consistent aligned 
microchannel architecture. Conduit section planes are shown in graphic overlays for each image. 
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3.3.3. Functional Recovery Evaluation 
3.3.3.1. Sciatic Functional Index 
The recovery of hindlimb motor function was assessed using walking track analysis evaluating a 
number of gait parameters, in particular, sciatic functional index (SFI) biweekly over the 8-week test period. 
Quantitative assessment of SFI ranges from 0 to -100, indicating normal function to complete dysfunction, 
respectively. As a baseline, a pre-operative SFI value of -10.15±1.18 (mean±SEM) was measured for all 
rats. There was a sharp decrease in SFI at 2 weeks post-operative for all surgical groups with values as 
follows: autograft (-57.37±2.13), conduit (-58.41±0.98), and drug-conduit (-52.62±3.38) (mean±SEM) 
(Figure 21). Fluctuating changes were quantified for all groups (excluding sham) at 4 weeks and 6 weeks 
post-operative, with 8-week SFI values as follows:  autograft (-44.89±4.73), conduit (-51.79±4.40), and 
drug-conduit (-45.12±4.45) (mean±SEM). There were no statistically significant (p<0.05) differences 
between any of the test groups (autograft, conduit, and drug conduit), however all test groups were 
significantly different than sham at all timepoints excluding the week 0 baseline. 
Figure 21: Sciatic functional index (SFI) compares geometric representations of injured hind paw to the contralateral 
uninjured paw, where values are scaled from ~-10 (representing nearly normal function) to ~-100 (dramatic injury). 
Improvements can be seen in test groups from 2-8 weeks post-operative, with autograft and drug-conduit groups having nearly 
identical trends. All data are shown as mean±SEM. n=4-6 per group per timepoint. *=p<0.05 vs sham. 
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3.3.3.2. Paw Area 
There was a dramatic decrease in paw area 2 weeks post-operative, compared to baseline, 
corresponding to the limited capability of toe spread of injured rats. Given the data representation for gait 
testing as a ratio of ipsilateral vs contralateral, naturally a value of approximately 100% is considered 
normal. Paw area values may also be affected by the rat heel, which drops with nerve injury, and may form 
a longer foot print. Paw area did not show a marked change over the 8-week study, with no statistically 
significant (p<0.05) differences between any of the test groups (autograft, conduit, and drug conduit) 
(Figure 22). All test groups were significantly different than sham at all timepoints excluding the week 0 
baseline. Paw area values 8 weeks post-operative were slightly lower than previous measurements, perhaps 
due to the relatively quicker healing of the aforementioned heel drop which would further decrease the 
footprint. The paw area values at 8 weeks post-operative were as follows: autograft (61.40±7.04%), conduit 
(62.30±2.82%), and drug-conduit (63.48±1.55%) (mean±SEM). 
 
Figure 22: Paw area reflects the size of the paw print during the stance phase, which decreases post-nerve injury. All data are 
shown as mean±SEM. Data are expressed as ratios between the ipsilateral (right) hind paw and the contralateral (left) hind 
paw times 100%. n=4-6 per group per timepoint. *=p<0.05 vs sham. 
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3.3.3.3. Swing Time 
Swing time refers to the period of time the foot is off of the surface, swinging forward during the 
gait cycle. Typically, swing time is increased as a result of injury, as animals are more reluctant to (or 
physically cannot) put weight on, or bear load with, the affected leg. This was quantified with the sciatic 
nerve transection, where 2 weeks post-operative there is an increase in swing time for all test groups (Figure 
23). The swing time stabilizes around 6 weeks post-operative with 8-week swing time values as follows: 
autograft (129.94±3.52%), conduit (144.31±18.66%), and drug-conduit (126.53±2.86%) (mean±SEM). At 
week 6 post-operative, sham values were determined to be statistically significant (p<0.05) to conduit only. 
At week 8 post-operative sham values were determined to be statistically significant (p<0.05) to autograft 
and conduit only. All other values were not significant. 
 
3.3.3.4. Stance Time 
Stance time refers to the period of time the foot is in contact with the surface. In direct contrast 
with swing time, typically stance time is decreased as a result of injury. A baseline average across all groups 
Figure 23: Duration of swing phase where the paw is not in contact with the glass runway, which increases post-nerve injury. 
All data are shown as mean±SEM. Data are expressed as ratios between the ipsilateral (right) hind paw and the contralateral 
(left) hind paw times 100%. n=4-6 per group per timepoint. *=p<0.05 vs sham. 
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of 98.27±0.96% (mean±SEM) was recorded for stance time (Figure 24). At 2 weeks post-operative, conduit 
showed the lowest value (81.54±5.99%), compared to autograft and drug conduit, however the value was 
only significant to that of sham animals (p<0.05). At 8 weeks post-operative all test groups did not show 
major changes from week 2 post-operative values, with 8 weeks post-operative values as follows: autograft 
(88.81±1.43%), conduit (84.59±2.50%), and drug-conduit (85.92±3.37%) (mean±SEM). Values for sham 
2 weeks post-operative were determined to be statistically significant (p<0.05) to conduit only. At 8 weeks 
post-operative sham values were determined to be statistically significant (p<0.05) to all three test groups. 
All other values were not significant. 
 
3.3.4. Nerve Morphology and Myelin Assessment 
Nerve regeneration was observed in all test groups 8 weeks after implantation with differing 
degrees of myelination (Figure 25a). Axon diameter was found to differ between groups where sham axons 
measured 5.87±5.46µm, autograft axons 3.42±2.89µm, conduit 5.78±8.80µm, and drug-conduit axons 
Figure 24: Duration of the stance phase where the paw is in contact with the glass runway, which decreases post-nerve injury. 
All data are shown as mean±SEM. Data are expressed as ratios between the ipsilateral (right) hind paw and the contralateral 
(left) hind paw times 100%. n=4-6 per group per timepoint. *=p<0.05 vs sham. 
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7.24±8.78µm (mean±SD) (Figure 25b). More importantly, assessment of myelin thickness using G-ratio 
measurements concluded that, autograft had the thickest myelin at 0.61±0.10, followed by drug-conduit at 
0.65±0.06, and conduit presented the thinnest myelin at 0.74±0.07 (mean±SD) (Figure 25c). These G-ratio 
values were compared to sham (0.57±0.08), where conduit and drug-conduit groups were significantly 
different (p<0.05) to sham, however autograft was not. Furthermore, autograft and drug-conduit groups 
were significantly different (p<0.05) to conduit values. 
 
3.3.5. Histological Evaluation 
Luxol fast blue, a myelin sheath stain that stains phospholipids (the main constituent of myelin) 
blue, was used for the assessment of myelin presence and distribution. All groups showed myelin 
Figure 25: Drug-conduit implants supported axon regeneration comparable with autografts at 8 weeks post-operation. (A) 
Transmission electron microscopy (TEM) of cross sections of the middle region of the regenerated sciatic nerve at 8 weeks post-
operation. Black arrows indicate unmyelinated C-fiber axons and white arrows indicate myelinated A-fiber axons. Images were 
obtained at 1000x magnification; Size bars=10 μm. (B) Scatter plot of axon diameter against G-ratio (axon diameter/fiber 
diameter) with logarithmic regression curves . (C) Test and control myelin sheath thicknesses (G-ratio). G-ratio is the ratio of 
inner axon diameter to outer fiber diameter. Data are expressed as mean±SD. n=35 measurements per group. #=p<0.05 vs 
sham, *=p<0.05 vs conduit. 
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production, as seen by the characteristic light blue staining of longitudinal sections (Figure 26a). When 
myelin was quantified, autograft (29.98±3.07%), conduit (26.34±3.99%), and drug-conduit (32.57±5.78%) 
were statistically significant (p<0.05) to sham (46.15±2.81%), however there was no significance between 
groups (Figure 26b). Using the same Luxol fast blue staining, the number of infiltrating cells for each 
group was quantified and expressed as fold change, normalized to sham values (Figure 26c). Analysis 
showed an increase in infiltrating immune cells for test groups, as expected. All three groups were 
statistically significant to sham, and autograft values (2.27±0.20) were statistically lower than conduit 
values (3.05±0.43). Autograft and drug-conduit values (2.81±0.55) were shown to be not significant. 
 
Figure 26: Myelin production and number of infiltrating immune cells were similar between drug-conduit and autograft at 8 
weeks post-operation. (a) Histological longitudinal sections of the middle region of the regenerated sciatic nerve stained for 
myelin (Luxol fast blue staining) at 8 weeks post-operation. Images were obtained at 20x magnification, where myelin is stained 
light blue and cell nuclei are stained violet; Size bars=200 μm. (b) Quantification of average myelin area (%) from the middle 
region of the regenerated nerve. (c) Number of infiltrating immune cells normalized to the sham group and expressed as fold 
change. Data are expressed as mean±SD, n=5 per group. #=p<0.05 vs sham, *=p<0.05 vs conduit. 
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In similar assessments, neurofilament-H (NF-H) and S100 were evaluated using appropriate 
immunohistochemical stains of longitudinal sections where the marker stains dark brown (Figure 27a). 
Staining for NF-H can be seen across all groups, with a noticeably lower content in the conduit group. 
Percent area values for NF-H were as follows: sham (22.49±2.16%), autograft (15.21±2.07%), conduit 
(6.37±0.81%), and drug-conduit (16.05±2.54%) (Figure 27b). All three test groups were statistically 
significant (p<0.05) to sham, and autograft and drug-conduit values were significantly greater than conduit, 
but were not significant to one another. S100 staining showed a similar trend to that of NF-H (Figure 27c), 
where autograft (30.66±2.86%), conduit (19.95±7.45%), and drug-conduit (34.06±1.23%) values were 
statistically significant (p<0.05) to sham values (42.01±3.22%). Again, autograft and drug-conduit values 
were statistically greater than conduit values, however were not significant to one another. 
 
Figure 27: Drug-conduit and autograft implants show similar neurogenic marker expression at 8 weeks post-operation. (a) 
Immunohistochemical histology assessment showing longitudinal sections of the middle region of the regenerated sciatic nerve 
stained for Neurofilament (NF-H) and S100 at 8 weeks post-operation. Images were obtained at 20x magnification; Size 
bars=200 μm. Marker proteins stain brown. (b) Quantification of average Neurofilament area (%) from the middle region of 
the regenerated nerve. (c) Quantification of average S100 area (%) from the middle region of the regenerated nerve. Data are 
expressed as mean±SD, n=5 per group. #=p<0.05 vs sham, *=p<0.05 vs conduit. 
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In an effort to investigate any potential toxicity of halloysite nanotubes, cross-sections of rat liver 
tissue were stained with hematoxylin and eosin (H&E). Figure 28 shows the histological assessment of 
hepatic tissues harvested from sham, autograft, conduit, and drug-conduit groups. The hepatic tissues in the 
control animals (sham and autograft) showed a normal hepatic architecture [233], and no differences were 
observed in the conduit and drug-conduit test groups, revealing that HNTs at the given dose had no 
remarkable adverse effects on the liver. No fatty degeneration, local hydropic degeneration, or spotted 
necrosis was observed in the hepatic tissue of conduit or drug-conduit groups, which may occur with HNT 
administration at particularly high doses, where systemic clearance and excretion is not sufficient [233, 
234]. 
 
Figure 28: No apparent hepatotoxicity was observed in HNT-containing conduits or any test group. Histological cross sections 
(H&E stain) of liver tissue in rats 8 weeks post-operation were used to assess potential toxicity of HNT conduits. Sham and 
autograft groups do not contain halloysite. No fatty degeneration, local hydropic degeneration, or spotted necrosis was observed 
in the hepatic tissue of conduit or drug-conduit groups, which may occur with HNT administration at high doses, where systemic 
clearance and excretion is not sufficient. Size bar=100 μm. 
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3.4. DISCUSSION 
The ultimate goal of all nerve repair and regeneration strategies is reestablishing continuation of 
the nerve channel to reinnervate the target tissue and conduct electrical impulses. The developed aligned 
conduit, delivering a sustained release of 4AP, showed successful nerve repair and regeneration, both 
histologically and functionally, showing regenerative efficacy equal to that of the gold-standard autograft 
(Figure 29). The critical-size sciatic nerve transection is a severe nerve injury model which results in 
significant sensory and motor loss of the hindlimb. Autologous nerve grafting (autograft) is considered to 
be the gold-standard treatment for PNI with a large segmented gap [235]. Due to several disadvantages of 
autografts, engineered nerve conduits have been developed as alternatives for segmental PNI treatment. 
Recent studies have shown the ability of nerve guidance conduits to improve the repair and regeneration 
across a nerve gap, with marked increases in functional recovery, which was also shown in our study. 
 
Chitosan is a natural, biodegradable, and versatile biopolymer which has been shown to be highly 
biocompatible and effectively used in antibacterial, antifungal, and regenerative medicine applications. The 
development of chitosan scaffolds for tissue engineering and regenerative medicine applications has been 
extensively studied with great successes, despite mechanical fragility and poor mechanical integrity. To 
Figure 29: Photograph of repaired sciatic nerve harvested at 8 weeks post-operative. The nerve is shown cut in cross-section at 
the central region, where the native proximal sciatic nerve can be seen in white (left), the 4AP drug-loaded conduit can be seen 
in the yellow/brown color, and regenerated sciatic nerve can be seen exposed through the conduit center (right).  
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combat such disadvantages, chitosan scaffolds can be doped with supporting compounds to allow for 
mechanical strengthening, creating a mechanically competent composite. Biopolymers are often doped with 
nanofillers which serve to increase the scaffolds’ mechanical strength, but can also enhance biological 
compatibility due to the surface irregularities of the scaffold pores, that arise due to the insoluble nanofillers, 
which promote cell adhesion. In our previous work, the doping of conduits with HNTs is detailed. 
Halloysite nanotubes can have lengths ranging from 0.3-1.5 μm, with an inner lumen that has a diameter of 
~40-70 nm. The neighboring alumina and silica layers, with differing waters of hydration, curve and form 
multilayer tubes due to a packing disorder. The innermost alumina surface is positively charged, while the 
outermost silicate surface is negatively charged [236]. The hollow lumen of HNTs provide excellent ability 
to carry, encapsulate, and transport drugs and biomacromolecules, where they can be effective in sustaining 
drug release while also controlling burst release characteristics of smaller, hydrophilic molecules. When 
mixed with cationic chitosan in a dilute acidic solution, the negatively-charged HNTs form a chitosan-HNT 
complex via electrostatic interactions. Furthermore, halloysite can form hydrogen bonds with the amino- 
and hydroxyl-groups of chitosan, further increasing the interfacial compatibility and dispersion of HNTs in 
chitosan [236].  
Typically, after severing the sciatic nerve, the rat is unable to walk normally up on its toes. As a 
result, the heel drops and forms a long foot print, until reinnervation of the nerve is established and muscle 
function is returned [230]. Post-injury, there is also a noticeable collapse of the affected limb toe spread 
which is slowly restored with regeneration of the sciatic nerve. Taking advantage of such post-injury 
changes, the calculation of sciatic functional index (SFI) serves as a strong indicator for functional recovery 
of the sciatic nerve. A sharp reduction in SFI was observed post-surgery, and the SFI noticeably increased 
over the eight-week test period. The equivalency of autograft and drug-conduit groups (-44.89±4.73 and -
45.12±4.45, respectively) at 8-weeks post-operative is a strong positive indicator of the efficacy of the drug-
conduit. Neat (no drug) conduit groups did not show any statistical differences from values of autograft and 
drug-conduit groups in functional assessments, which may reflect on the functional capabilities of the 
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aligned microchannel porosity to physically guide regenerating axons, improving target reinnervation. 
Autograft and drug-conduit groups performed virtually identically in quantifications of paw area, swing 
time, and stance time, further confirming the drug-conduit’s ability to improve functional recovery post-
nerve transection. 
The endogenous repair of transected PNI is marked by three broad phases: Wallerian degeneration, 
axonal regeneration, and target-organ reinnervation. Schwann cells are vital primary mediators of the 
cascading events of Wallerian degeneration, including the recruitment of macrophages, along with 
increases in critical factors including brain-derived neurotrophic factor (BDNF) and nerve growth factor 
(NGF) [42-44]. The ability of the small-molecule drug 4AP to increase BDNF and NGF release in Schwann 
cells in vitro was shown in a previous publication [69]. Schwann cells are also critical in the alteration of 
gene expression, removal of myelin, formation of Bands of Büngner, and axon regeneration and re-
myelination. The protein marker S100 exists only in glial cells of the central nervous system and Schwann 
cells of the peripheral nervous system. Many S100-positive Schwann cells were observed via 
immunohistochemical staining in all groups, with autograft and drug-conduit groups showing relatively 
equal levels of S100, significantly greater than neat (no-drug) conduit groups. The increased expression of 
S100 may be a result of increased Schwann cell recruitment to the injury site due to chemotactic effects of 
amplified neurotransmitter release as a direct result of 4AP administration. This trend was also seen with 
the detection of neurofilament-H (NF-H), a neurofilament protein which is a primary component of the 
mature neuronal cytoskeleton, and significantly downregulated at the early period following axonal 
transection [237]. When neurofilament-positive axons were quantified, levels were not significantly 
different between autograft and drug-conduit groups, which both showed higher levels than neat (no-drug) 
conduit groups.  
The degree of repair and regeneration achieved by the nerve conduit was further confirmed by the 
investigation of myelin production and thickness, both histologically and using TEM. Using a Luxol Fast 
Blue stain for myelin, histological studies revealed abundant, well-myelinated axons in the mid-portion of 
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the regenerated nerve. Autograft groups showed no statistical differences compared to both neat conduit 
and drug-conduit groups. Similarly, in TEM morphometric studies, myelin thickness was calculated to be 
statistically equivalent between autograft and drug-conduit groups, which were significantly greater than 
neat (no-drug) conduit groups (smaller G-ratio). This is perhaps attributed to the ability of 4AP drug to 
upregulate the release of myelin proteins in Schwann cells, including myelin protein zero (P0), which was 
shown in our previous publication [69]. 
We conducted several extensive studies and assessments to evaluate peripheral nerve regeneration 
using our previously developed and characterized nerve guidance conduit. The advantages of the nerve 
guidance conduit were (1) the aligned microchannel porosity, which can physically guide the regenerating 
axons across the injury gap for better distal target reinnervation; and (2) the sustained release of small-
molecule 4AP drug which can increase nerve conduction, increasing the release of synaptic 
neurotransmitters and critical Schwann cell neurotrophic factors including BDNF, NGF, and myelin protein 
zero. Studies showed varying levels of nerve regeneration across the autograft, conduit, and drug-conduit 
groups. All three groups showed successful increases in functional recovery without significant differences, 
however, the drug-conduit outperformed the neat (no drug) conduit in terms of histological and 
morphometric evaluations of myelin, S100, and NF-H. Overall, the drug-conduit showed equivalency to 
autograft repair in a majority of the functional, morphological, and histological assessments. These results 
indicate the success of the conduit’s aligned microchannel architecture to facilitate physical guidance and 
reinnervation, but also highlight the enhanced efficacy of regeneration achieved by the drug conduit, a 
testament to the contributions of 4AP to the repair and regeneration process. This represents a significant 
advance in the fields of peripheral nerve repair, regeneration, and engineering, where the developed aligned 
nerve guidance conduit was shown to be a clinically feasible drug delivery vehicle for small molecule drug 
4AP in vivo, showing its strong ability to treat peripheral nerve injury. 
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3.5. CONCLUSION 
The present study looked at novel nerve guidance conduits with aligned microchannel porosity 
delivering a sustained release of 4-Aminopyridine for peripheral nerve regeneration in a critical-size rat 
sciatic nerve transection model. The results of functional walking track analysis, morphometric evaluations 
of myelin development, and histological assessments of various markers confirmed the equivalency of 
implanted drug-conduits repair to autograft control treatments. The conduit’s aligned microchannel 
architecture may play a vital role in facilitating physical guidance and distal target reinnervation, while the 
sustained release of 4-Aminopyridine may increase nerve conduction, and in turn synaptic neurotransmitter 
release and upregulation of critical Schwann cell neurotrophic factors, which further aid in more efficient 
and efficacious peripheral nerve regeneration via a drug delivery system that is feasible for clinical 
application. 
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CHAPTER 4: SUMMARY OF FINDINGS 
The presented project describes, in detail, engineering efforts to combat slow and ineffective 
peripheral nerve injury repair by investigating, and later, developing and testing a novel approach to 
peripheral nerve regeneration. A nerve guidance conduit was developed in order to bridge peripheral nerve 
defect injuries, in an effort to help promote more efficient and successful nerve repair and regeneration. 
Chemically composed of chitosan, a natural, biodegradable, biocompatible, and FDA-approved polymer, 
the nerve guidance conduit was developed and fully characterized for physiochemical properties. In an 
effort to enhance regenerative cues, aligned microchannel porosity was created within the conduit structure 
using a unidirectional freezing technique (Figure 30). Such physical cues will help correctly guide 
sprouting axons to re-innervate the target distal organ more effectively. Due to chitosan’s poor mechanical 
integrity, halloysite nanotubes were added as filler composite material, which served to increase the 
mechanical strength of the conduit system, and also acted as the primary drug-delivery vehicle for the 
selected drug, 4-Aminopyridine. The inclusion of halloysite nanotubes was shown to be homogenous and 
was shown to have no significant impacts on physiological toxicity. The composite structure was shown to 
have adequate mechanical modulus, within comparable range of native peripheral nerve. 
 
The composite nerve guidance conduit was further tested for biodegradation properties and human 
Schwann cell viability. The degradation profile of the polymer system was characterized using standard 
Figure 30: Summary of key advantages of the developed nerve guidance conduit system. 
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calculations over a 12-week period. The degradation was visually inspected by performing SEM over the 
course of the testing period. Cell viability on the conduit structure was analyzed using a standard MTS cell 
assay as well as fluorescent microscopy. The conduit showed adequate cell attachment and viability, with 
normal cell proliferation, and showed longitudinal alignment of cells according to the aligned nature of the 
polymer matrix. 
4-Aminopyridine, an FDA-approved small molecule voltage-gated potassium channel blocker, was 
successfully loaded into halloysite nanotubes and incorporated into the composite nerve guidance conduit 
structure. The release of 4-Aminopyridine drug was fully characterized from a variety of conduit 
formulations, including from halloysite nanotubes without a polymer matrix. The drug release profiles were 
also fit to multiple kinetic release models which were in agreement with the findings. The final composite 
structure achieved sustained release of 4-Aminopyridine, showing only ~30% drug release within 7 days. 
The loading of 4-Aminopyridine into halloysite nanotubes prior to inclusion into the polymer matrix 
showed a tremendous boost in controlling the burst release of drug typically seen with small-molecules 
from polymeric systems.  
The effect of 4-Aminopyridine on human Schwann cells was tested in vitro in a systematic 
assessment of cytotoxicity, proliferation, and protein expression. Human Schwann cells were treated with 
a wide range of 4-Aminopyridine doses (0.001-10 µg/mL) and evaluated for cytotoxicity using a standard 
LDH assay, which showed no significant differences in cell activity between groups, indicating no 
cytotoxicity. The proliferation of Schwann cells was investigated when treated with 1, 5, and 10 µg/mL of 
4-Aminopyridine and compared to a no-drug control. Early timepoints of 1- and 7-days post-seeding 
showed no differences in cell proliferation, however at 14- and 21-days post-seeding, 4-Aminopyridine 
decreased cell proliferation when compared with the no-drug control. This decrease in proliferation was in 
agreement with findings in literature and was further confirmed with evaluations of protein expression. 
Immunofluorescent staining was used to evaluate the expression of three key neurotrophic factors: nerve 
growth factor (NGF), myelin protein zero (P0), and brain-derived neurotrophic factor (BDNF). At 14 days 
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post-seeding, 4-Aminopyridine showed a dose-dependent increase in all three protein markers. These 
increases in neurotrophic factor expression can be directly correlated to the aforementioned decreases in 
proliferation, where past literature states that proliferation and myelin differentiation have been proven to 
be incompatible processes, unable to occur concurrently both in vitro and in vivo. A summary of key in 
vitro findings and achievements is shown in Figure 31. 
 
To test the feasibility and efficacy of the drug-delivery conduit in vivo, a 15 mm (critical size) 
sciatic nerve defect was created in female Wistar rats, serving as a severe peripheral nerve injury model. 
The nerve defect was bridged and repaired with an autograft control, a neat (no-drug) conduit, and a 4AP 
drug-loaded conduit. Over an 8-week test period, the animals were subjected to walking track analysis 
where gait parameters were measured as an analysis of functional recovery. After 8-weeks post-operative, 
animals were euthanized and nerve repair and regeneration was evaluated using several histological stains 
Figure 31: Key in vitro findings and achievements. 
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and myelin development was evaluated using electron microscope. The results of functional walking track 
analysis, morphometric evaluations of myelin development, and histological assessments of various 
markers confirmed the equivalency of the drug-conduit repair to autograft controls. Repaired nerves show 
formation of thick myelin, presence of S100 and Neurofilament markers, and promising functional 
recovery. Although the neat (no-drug) conduit showed positive nerve regeneration, it was deficient 
compared to the regenerative efficacy of autograft and drug-conduits. A summary of key in vivo findings 
and achievements is shown in Figure 32. 
 
Overall the nerve guidance conduit achieved peripheral nerve regeneration across a critical size 
nerve defect. The drug-conduit’s performance was measured to be statistically equivalent to the gold-
standard autograft in a majority of the performed evaluations, including the assessment of functional 
recovery. The conduit’s aligned microchannel architecture may play a vital role in physically guiding axons 
Figure 32: Key in vivo findings and achievements. 
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to distal target re-innervation, while the sustained release of 4-Aminopyridine may increase nerve 
conduction, and in turn synaptic neurotransmitter release and upregulation of critical Schwann cell 
neurotrophic factors. This facilitates more efficient and efficacious peripheral nerve regeneration via a drug 
delivery system that is feasible for clinical application, with potentially transformative implications. 
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CHAPTER 5: FUTURE PERSPECTIVES  
Clinically, the repair of peripheral nerve injuries is positioned at a crossroads of medical disciplines, 
namely orthopedics and neurosurgery. However, surgeons classically trained in the nervous system and 
neurosurgery most commonly operate in the areas of the central nervous system. As such, most (particularly 
mild and moderate) peripheral nerve repair falls to trauma surgery and orthopedic surgery professionals. 
Clinical investigation of endogenous repair mechanisms, neuroma (scar-tissue) prevention strategies, 
endplate re-innervation modalities, as well as cellular involvements and biochemical pathways are critical 
for future improvements to nerve repair, re-innervation, and functional recovery. The overwhelming 
amount of research and development focused on cellular, pharmaceutical, and bioengineering modalities to 
further improve peripheral nerve repair and regeneration, as well as patient outcome, is a testament to the 
severity of the unmet clinical need and the potentially transformative implications of any such treatment 
alternatives. A summary of key future directions and scientific perspectives is shown in Figure 33. 
 
Ideally, a nerve guidance conduit (NGC) systems needs to be biocompatible, biodegradable, 
adequately flexible yet suturable, and should have a combination of physical topographic cues as well as 
biological agents for enhanced repair and regeneration. To date, researchers around the world have 
developed various strategies in combination with NGC for improved regeneration outcomes. The 
transplantation of Schwann cells as well as stem cells (adipose-derived, mesenchymal, neural, etc.) have 
Figure 33: Future directions of the field and scientific perspectives 
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shown successes in combination with NGCs, but pose feasibility concerns with translation to clinic. The 
use of biopolymer surface modification and the delivery of growth factors (NGF, GDNF, BDNF, VEGF, 
NT-3, etc.) and drugs have also been popularly researched. More recently, physical stimuli such as 
ultrasound and electrical stimulation have been investigated for their regenerative effects. Lastly, genetic 
manipulation, by means of transfection and viral vectors has been attempted, but is still considered non-
translatable.  
Given the complex nature of peripheral nerve injury, repair, and regeneration there have been few 
tissue engineering developments to currently used treatments, mainly citing clinical feasibility concerns 
(design, logistical, or financial) and differing preclinical and clinical results. This highlights the unmet need 
for better preclinical models focused on optimized clinical feasibility and translatability, in order for tested 
tissue engineering approaches to successfully bridge the lab-to-clinic gap [238]. Promising technologies, 
such as lab-on-a-chip methods, exist and are being developed which hold significant promise for more 
accurate and relevant in vitro testing models [239]. The combination of pharmaceutical and molecular 
therapies (i.e. protein and RNA delivery) will undoubtedly be involved for enhancement of peripheral nerve 
repair and regeneration. In combination with novel surgical techniques, the use of new nerve guidance 
conduits and constructs may alleviate shortcomings of traditional autografts and allografts to facilitate. 
Future directions aimed at the delivery of biomacromolecules, such as silencing RNAs (siRNA), proteins 
and peptides, and DNA therapies may facilitate intrinsic growth mechanisms, potentially leading to more 
natural, endogenous growth and repair [240]. The rapid developmental growth of 3-dimensional (3D) 
printing technologies also hold high promise in such fields which may revolutionize the repair of peripheral 
nerve injuries with patient-specific parameters for more accurate and helpful nerve guidance conduits [239]. 
In the future development of new nerve constructs, the use of modern techniques such as 3D-
printing, laser fabrication, two-photon and single-photon stereo lithography, extrusion-based fabrication, 
and rapid prototyping will undoubtedly result in the fabrication of more complicated constructs with very 
high degrees of accuracy. These modern technologies may enable the ability to more accurately mimic 
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nerve anatomy and architecture, such as bands of Büngner, leading to more endogenous-like repair. 
Furthermore, the use of modern fabrication techniques such as 3D-printing and extrusion-based fabrication 
may facilitate the manufacturing of structures with advanced geographical features including capillary 
blood vessels and other vasculature, which will become increasingly important as constructs are developed 
for larger defects. The ability to accurately predict such fabrication and performance using computer and 
mathematical modeling will continue to be a useful tool in the design of new NGCs. Lastly, more rigorous 
in vitro testing as well as more translatable in vivo testing, by means of large animal studies, will be required 
to determine the efficacy of such constructs to successfully bridge the lab-to-clinic gap. 
Despite the successes of the current study, there are several limitations. Firstly, due to greater 
variability in functional assessments, the number of animals in each group may need to be increased to 
obtain more walking track data points, which may help in the identification of statistically significant 
improvements between groups. Second, it is possible that functional differences between groups, 
specifically the neat (no-drug) conduit and drug-conduit, may be evident at later time points given the 
differences observed in TEM and histology between these groups at the 8-week post-operative time point. 
As such, extended the study to include future timepoints may yield more evident changes and improvements 
in functional recovery. Nevertheless, the functional assessments provided key insights into differences 
between the groups, and highlighted the performance equivalence between the control autograft and test 
drug-conduit. Third, the release of 4AP was not quantified and characterized in vivo. The quantification 
and optimization of 4AP released in vivo will be critical to harness the full capabilities of this drug for 
optimized nerve regeneration. According to the pathophysiology of peripheral nerve injury and repair, the 
first 7-21 days offer the greatest potential for facilitated regeneration as this is the period of Wallerian 
degeneration, cell recruitment, and the beginning of axonal regeneration. As such, this will be the period 
where 4AP will have the greatest functional impacts. The dosing of drug in the implanted conduits should 
be evaluated, modified, and optimized in future studies. 
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